Receptor-interacting protein 1 inhibitors including piperazine heterocyclic amide ureas
By developing compounds of formula Ia and formula I to inhibit RIP1 kinase, the problems of cellular necrosis, apoptosis, and ferroptosis were addressed, enhancing the efficacy of tumor immunotherapy and demonstrating pharmacokinetic advantages, overcoming drug resistance caused by RIP1 kinase activity.
Patent Information
- Application Number
- CN202180036816.8
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Priority Date
- 2020-05-20
- Filing Date
- 2021-05-20
- Publication Date
- 2024-11-22
- Estimated Expiration
- 2041-05-20
AI Technical Summary
Existing technologies are insufficient to effectively inhibit necroptosis, necrosis, and ferroptosis, especially in tumor immunotherapy, where drug resistance caused by RIP1 kinase activity and the problem of immune checkpoint kinases have not been effectively addressed.
A class of compounds, including compounds of formula Ia and I and their prodrugs, has been developed. These compounds are hydrolyzed in the intestine or blood to their respective inhibitors, exhibiting abnormal metabolic stability and the ability to specifically inhibit RIP1 kinase, thereby blocking necrotic apoptosis and ferroptosis.
It provides effective inhibition of RIP1 kinase, reduces cellular necrosis, apoptosis, and ferroptosis, enhances the efficacy of tumor immunotherapy, overcomes drug resistance issues, and demonstrates pharmacokinetic advantages supported by abnormal metabolic stability and liver microsomal data.
Smart Images

Figure BDA0003953715090000021 
Figure BDA0003953715090000026 
Figure BDA0003953715090000161
Abstract
Description
[0001] This application claims priority to international patent application No. PCT / CN2020 / 091429 filed on May 20, 2020, the entire contents of which are incorporated herein by reference. Background Art
[0002] Tumor necrosis factor alpha (TNF-α)-induced NF-κB activation plays a central role in the immune system and inflammatory responses. Receptor interacting protein 1 (RIP1) is a multifunctional signal transducer that is involved in mediating nuclear factor κB (NF-κB) activation, apoptosis, and necroptosis. The kinase activity of RIP1 is closely related to mediating necroptosis, a type of necrotic cell death that is independent of the caspase pathway. Holler et al. Nat Immunol 2000; 1: 489-495; Degterev et al. Nat Chem Biol 2008; 4: 313-321.
[0003] Necrotosis plays a role in various pathological forms of cell death, including ischemic brain injury, neurodegenerative diseases and viral infection. Dunai et al. Dec 2011, Pathol. Oncol. Res.: POR 17(4):791-800. Necrostatin-1 (Nec-1) is a small molecule inhibitor of RIP1 kinase activity that blocks necroptosis. Degterev et al. Nat Chem Biol 2005; 1:112-119.
[0004] RIP1 can promote D-1 immunotherapy resistance (e.g. Manguso et al. 2017 Nature 547, 413-418) and can serve as a checkpoint kinase to control tumor immunity (e.g. Wang et al. Cancer Cell 34, 757-774, Nov 12, 2018).
[0005] Related patent publications include: US9974762, US10092529, US6756394, US8278344, US20120122889, US20090099242, US20100317701, US20110144169, US20030083386, US201200309795, WO2009023272, WO2010075290, WO2010075561, WO2012125544, and WO2020 / 103884. Summary of the invention
[0006] The present invention provides compounds as inhibitors of necrosis, necroptosis, ferroptosis, human receptor interacting protein 1 kinase (RIP1) or related indications, and prodrugs thereof, which are generally hydrolyzed in the intestine or blood to produce the corresponding inhibitors. In embodiments, the inhibitors provide unexpected abnormal metabolic stability, as evidenced by liver microsome data and PK data.
[0007] In one aspect, the present invention provides a compound of formula Ia:
[0008]
[0009] R1 is C6 aryl including 0 or 1 N heteroatoms, optionally substituted at C3 and / or C5 by halogen or CN;
[0010] R2 is C6 aryl including 0, 1 or 2 N heteroatoms, optionally substituted at C4 by halogen or C1-C3 alkoxy;
[0011] Y is O or N;
[0012] When Y is N, m is 2, and yes
[0013] When Y is O, m is 1, and yes
[0014] R3 and R4 are independently H or alkyl or cycloalkyl or -ORs, for example, H or C1-C6 alkyl or cycloalkyl or -ORs, for example H or C1-C3 alkyl or C3-C6 cycloalkyl or -ORs, wherein Rs is C1-C6 alkyl optionally substituted with halogen and C3-C6 cycloalkyl; wherein alkyl and cycloalkyl, or C1-C6 alkyl and cycloalkyl, or C1-C3 alkyl and C3-C6 cycloalkyl are each independently substituted with 0-3 substituents selected from halide / halogen, optionally substituted N, S or O, and optionally substituted hydrocarbon, wherein R3 and R4 may be attached in a heterocycle;
[0015] or a salt, a hydrate or a stereoisomer thereof.
[0016] In one aspect, the present invention provides a compound of formula I:
[0017]
[0018] R1 is C6 aryl including 0 or 1 N heteroatoms, optionally substituted at C3 and / or C5 by F or CN;
[0019] R2 is C6 aryl including 0, 1 or 2 N heteroatoms, optionally substituted at C4 by F;
[0020] R3 and R4 are independently H or C1-C3 alkyl substituted with 0-3 substituents selected from halide / halogen, optionally substituted N, S or O, and optionally substituted hydrocarbyl, wherein R3 and R4 may be attached in a heterocyclic ring;
[0021] or a salt, a hydrate or a stereoisomer thereof.
[0022] In various embodiments:
[0023] The R3 and R4 substituents are independently C0-C6: aldehyde, aldimine, alkanoyloxy, alkoxy, alkoxycarbonyl, alkoxy, alkyl, alkenyl, alkynyl, amine, azo, halogen, carbamoyl, carbonyl, carboxyl, cyano, ester, haloformyl, peroxyhydroxy, hydroxy, imine, isocyano, isocyanate, N-tert-butoxycarbonyl, nitrate, nitrile, nitrite, nitro, nitroso, phosphate, phosphono, thioether, sulfonyl, sulfo, mercapto, thiol, thiocyano, trifluoromethyl or trifluoromethyl ether (OCF3);
[0024] R2 includes N2, N4 or N2 / N4; or
[0025] Any combination of the above substituents.
[0026] In a certain aspect, the invention provides compounds having structures disclosed herein.
[0027] In a certain aspect, the present invention provides a pharmaceutical composition comprising a therapeutically effective amount of a compound disclosed herein, a salt, hydrate or stereoisomer thereof and one or more pharmaceutically acceptable excipients in a predetermined unit dosage form.
[0028] In a certain aspect, the present invention provides the use of a compound, a salt, a hydrate or a stereoisomer thereof, or a composition disclosed herein in the preparation of a medicament for inhibiting necrosis, necroptosis, ferroptosis, human RIP1, or related indications in a human in need thereof.
[0029] In a certain aspect, the present invention provides a compound disclosed herein, a salt, hydrate or stereoisomer thereof, or a composition for use in inhibiting necrosis, necroptosis, ferroptosis, human RIP1, or related indications in a human in need thereof, or for use in the manufacture of a medicament thereof in a human in need thereof.
[0030] In a certain aspect, the present invention provides a method of using a compound, a salt, a hydrate or a stereoisomer thereof, or a composition disclosed herein to inhibit necrosis, necroptosis, ferroptosis, human RIP1, or related indications in a human in need thereof, or to manufacture a medicament thereof in a human in need thereof.
[0031] The present invention encompasses all combinations of specific embodiments described herein, as if each combination had been expressly recited. DETAILED DESCRIPTION
[0032] It should be understood that the embodiments and implementations described herein are for illustrative purposes only and that various modifications or variations thereto will be proposed to those skilled in the art and will be included within the spirit and scope of the present application and within the scope of the appended claims. All publications, patents, and patent applications cited herein are incorporated herein by reference in their entirety for all purposes.
[0033] The term "alkyl" refers to a hydrocarbon group selected from straight and branched chain saturated hydrocarbon groups of 1-18, or 1-12, or 1-6, or 1-3 carbon atoms. Examples of alkyl groups include methyl, ethyl, 1-propyl or n-propyl ("n-Pr"), 2-propyl or isopropyl ("i-Pr"), 1-butyl or n-butyl ("n-Bu"), 2-methyl-1-propyl or isobutyl ("i-Bu"), 1-methylpropyl or sec-butyl ("s-Bu"), and 1,1-dimethylethyl or tert-butyl ("t-Bu"). Other examples of alkyl groups include 1-pentyl, 2-pentyl, 3-pentyl, 2-methyl-2-butyl, 3-methyl-2-butyl, 3-methyl-1-butyl, 2-methyl-1-butyl, 1-hexyl, 2-hexyl, 3-hexyl, 2-methyl-2-pentyl, 3-methyl-2-pentyl, 4-methyl-2-pentyl, 3-methyl-3-pentyl, 2-methyl-3-pentyl, 2,3-dimethyl-2-butyl and 3,3-dimethyl-2-butyl.
[0034] Lower alkyl means 1-8, preferably 1-6, more preferably 1-4 carbon atoms, for example, 1-3 carbon atoms, and lower alkenyl or alkynyl means 2-8, 2-6 or 2-4 carbon atoms.
[0035] The term "alkenyl" refers to a hydrocarbon group selected from straight and branched hydrocarbon groups including at least one C=C double bond and 2-18, or 2-12, or 2-6 carbon atoms. Examples of alkenyl groups can be selected from ethenyl or vinyl, prop-1-enyl, prop-2-enyl, 2-methylprop-1-enyl, but-1-enyl, but-2-enyl, but-3-enyl, but-1,3-dienyl, 2-methylbut-1,3-diene, hex-1-enyl, hex-2-enyl, hex-3-enyl, hex-4-enyl, and hex-1,3-dienyl groups.
[0036] The term "alkylene" refers to a hydrocarbon group selected from straight and branched hydrocarbon groups containing a =C double bond and 1-18, or 1-12, or 1-6, or 1-3 carbon atoms, wherein the point of attachment is at the =C group of the alkylene group. For example, in In the formula (A), the cyclobutene is substituted by a C1 alkylene group, ie, a methylene group.
[0037] The term "alkynyl" refers to a hydrocarbon group selected from straight and branched hydrocarbon groups including at least one C≡C triple bond and 2-18, or 2-12, or 2-6 carbon atoms. Examples of alkynyl groups include ethynyl, 1-propynyl, 2-propynyl (propargyl), 1-butynyl, 2-butynyl, and 3-butynyl groups.
[0038] The term "cycloalkyl" refers to a hydrocarbon group selected from saturated and partially unsaturated cyclic hydrocarbon groups, including monocyclic and polycyclic (e.g., bicyclic and tricyclic) groups. For example, the cycloalkyl group can be 3-12, or 3-8, or 3-6, or 3-4, or 5-6 carbon atoms. Even further, for example, the cycloalkyl group can be a monocyclic group of 3-12, or 3-8, or 3-6, or 5-6 carbon atoms. Examples of monocyclic cycloalkyl groups include cyclopropyl, cyclobutyl, cyclopentyl, 1-cyclopent-1-enyl, 1-cyclopent-2-enyl, 1-cyclopent-3-enyl, cyclohexyl, 1-cyclohex-1-enyl, 1-cyclohex-2-enyl, 1-cyclohex-3-enyl, cyclohexadienyl, cycloheptyl, cyclooctyl, cyclononyl, cyclodecyl, cycloundecyl, and cyclododecyl groups. Examples of bicyclic cycloalkyl groups include those having 7-12 ring atoms arranged as a bicyclic ring selected from [4,4], [4,5], [5,5], [5,6] and [6,6] ring systems, or arranged as a bridged bicyclic ring selected from bicyclo[2.2.1]heptane, bicyclo[2.2.2]octane, and bicyclo[3.2.2]nonane. The ring may be saturated or have at least one double bond (i.e., partially unsaturated), but is not fully conjugated and is not aromatic as aromatic is defined herein.
[0039] The term "aryl" herein refers to a group selected from the following: 5- and 6-membered carbocyclic aromatic rings, for example, phenyl; bicyclic ring systems such as 7-12 membered bicyclic ring systems, wherein at least one ring is carbocyclic and aromatic, for example selected from naphthalene, indane, and 1,2,3,4-tetrahydroquinoline; and tricyclic ring systems such as 10-15 membered tricyclic ring systems, wherein at least one ring is carbocyclic and aromatic, for example, fluorene.
[0040] For example, the aryl group is selected from 5 and 6-membered carbocyclic aromatic rings fused to 5 to 7-membered cycloalkyl or heterocyclic rings, which optionally include at least one heteroatom selected from N, O, and S, provided that when the carbocyclic aromatic ring is fused to the heterocyclic ring, the point of attachment is located at the carbocyclic aromatic ring, and when the carbocyclic aromatic ring is fused to the cycloalkyl group, the point of attachment can be located at the carbocyclic aromatic ring or at the cycloalkyl group. Divalent groups formed by substituted benzene derivatives and having free valences on the ring atoms are called substituted phenylene groups. Divalent groups derived from monovalent polycyclic hydrocarbon groups (whose names end with "-yl") by removing one hydrogen atom from a carbon atom having free valences are named by adding "-idene" to the name of the corresponding monovalent group, for example, a naphthyl group with two points of attachment is called naphthylidene.
[0041] The term "halogen" or "halo" refers to F, Cl, Br or I.
[0042] The term "heteroalkyl" refers to an alkyl group that includes at least one heteroatom.
[0043] The term "heteroaryl" refers to a group selected from:
[0044] 5- to 7-membered aromatic, e.g., 5- to 6-membered aromatic monocyclic ring, which includes 1, 2, 3 or 4 heteroatoms selected from N, O, and S, the remaining ring atoms being carbon;
[0045] 8 to 12 membered bicyclic rings comprising 1, 2, 3 or 4 heteroatoms selected from N, O, and S, the remaining ring atoms being carbon and wherein at least one ring is aromatic and at least one heteroatom is present in the aromatic ring; and
[0046] An 11 to 14 membered tricyclic ring comprising 1, 2, 3 or 4 heteroatoms selected from N, O, and S, the remaining ring atoms being carbon and wherein at least one ring is aromatic and at least one heteroatom is present in the aromatic ring.
[0047] For example, heteroaryl groups include a 5- to 7-membered heterocyclic aromatic ring fused to a 5- to 7-membered cycloalkyl ring. For such fused, bicyclic heteroaryl ring systems, where only one of the rings includes at least one heteroatom, the point of attachment can be at the heteroaromatic ring or at the cycloalkyl ring.
[0048] When the total number of S and O atoms in the heteroaryl group exceeds 1, those heteroatoms are not adjacent to each other. In some embodiments, the total number of S and O atoms in the heteroaryl group is no more than 2. In some embodiments, the total number of S and O atoms in the aromatic heterocycle is no more than 1.
[0049] Examples of heteroaryl groups include, but are not limited to, (as numbered from the attachment position assigned a priority of 1) pyridyl (e.g., 2-pyridyl, 3-pyridyl, or 4-pyridyl), cinnolinyl, pyrazinyl, 2,4-pyrimidinyl, 3,5-pyrimidinyl, 2,4-imidazolyl, imidazopyridinyl, isoxazolyl, oxazolyl, thiazolyl, isothiazolyl, thiadiazolyl, tetrazolyl, thienyl, triazinyl, benzothienyl, furanyl, benzofuranyl, benzimidazolyl, indolyl, isoindolyl, indolinyl, phthalazinyl, pyrazinyl, pyridazinyl, pyrrolyl, triazolyl, quinolinyl, isoquinolinyl, pyrazolyl, pyrrolopyridinyl (e.g., 1H-pyrrolo[2,3-b]pyridin-5-yl), pyrazolopyridinyl (e.g., 1H-pyrazolyl), benzo[d]oxazol-6-yl), pteridinyl, purinyl, 1-oxa-2,3-oxadiazolyl, 1-oxa-2,4-oxadiazolyl, 1-oxa-2,5-oxadiazolyl, 1-oxa-3,4-oxadiazolyl, 1-thia-2,3-oxadiazolyl, 1-thia-2,4-oxadiazolyl, 1 -thia-2,5-diazolyl, 1-thia-3,4-diazolyl, furazanyl, benzofurazanyl, benzothiophenyl, benzothiazolyl, benzoxazolyl, quinazolinyl, quinoxalinyl, naphthyridinyl, furapyridinyl, benzothiazolyl (e.g., benzo[d]thiazol-6-yl), indazolyl (e.g., 1H-indazol-5-yl) and 5,6,7,8-tetrahydroisoquinoline.
[0050] The term "heterocyclic" or "heterocycle" or "heterocyclyl" refers to a ring selected from 4 to 12 membered, e.g., 3 to 6 membered, or 3 to 5 membered, or 4 to 5 membered, or 5 to 6 membered, or 4 to 6 membered, monocyclic, bicyclic and tricyclic, saturated and partially unsaturated rings including at least one carbon atom in addition to 1, 2, 3 or 4 heteroatoms selected from oxygen, sulfur, and nitrogen. "Heterocycle" also refers to a 5 to 7 membered heterocyclic ring including at least one heteroatom selected from N, O, and S fused to a 5, 6, and / or 7 membered cycloalkyl, carbocyclic aromatic or heteroaromatic ring, provided that when the heterocyclic ring is fused to a carbocyclic aromatic or heteroaromatic ring, the point of attachment is at the heterocyclic ring, and when the heterocyclic ring is fused to a cycloalkyl, the point of attachment can be at the cycloalkyl or heterocyclic ring.
[0051] "Heterocycle" also refers to an aliphatic spirocyclic ring including at least one heteroatom selected from N, O, and S, provided that the point of attachment is at the heterocyclic ring. The ring may be saturated or have at least one double bond (i.e., partially unsaturated). The heterocyclic ring may be oxo-substituted. The point of attachment may be at a carbon or heteroatom in the heterocyclic ring. A heterocyclic ring is not a heteroaryl as defined herein.
[0052] Examples of heterocycles include, but are not limited to, (as numbered from the attachment position assigned a priority of 1) 1-pyrrolidinyl, 2-pyrrolidinyl, 2,4-imidazolidinyl, 2,3-pyrazolidinyl, 1-piperidinyl, 2-piperidinyl, 3-piperidinyl, 4-piperidinyl, 2,5-piperazinyl, pyranyl, 2-morpholinyl, 3-morpholinyl, oxirane, aziridine, thiirane, azetidinyl, oxetanyl, thiirane, 1,2 -dithietanyl, 1,3-dithietanyl, dihydropyridinyl, tetrahydropyridinyl, thiomorpholinyl, thiooxanyl, piperazinyl, homopiperazinyl, homopiperidinyl, azepanyl, oxanyl, thioheptanyl, 1,4-oxathianyl, 1,4-dioxanyl, 1,4-oxathianyl, 1,4-oxazepanyl, 1,4-dithiacyclo heptyl, 1,4-thiazepanyl and 1,4-diazepanyl, 1,4-dithiacyclohexyl, 1,4-azathiacyclohexyl, oxazepine, diazepine, thiazepine, dihydrothiophenyl, dihydropyranyl, dihydrofuranyl, tetrahydrofuranyl, tetrahydrothiophenyl, tetrahydropyranyl, tetrahydrothiopyranyl, 1-pyrrolinyl, 2-pyrrolinyl, 3-pyrrolinyl, dihydroindole, 2H 1-oxo-1-thiomorpholinyl, ...
[0053] The term "fused ring" as used herein refers to a polycyclic ring system, such as a bicyclic or tricyclic ring system, in which the two rings share only two ring atoms and a common bond. Examples of fused rings may include fused bicyclic cycloalkyl rings such as those having 7-12 ring atoms arranged in a bicyclic form selected from [4,4], [4,5], [5,5], [5,6] and [6,6] ring systems as described above; fused bicyclic aryl rings such as the 7 to 12 membered bicyclic aryl ring systems described above, fused tricyclic aryl rings such as the 10 to 15 membered tricyclic aryl ring systems described above; fused bicyclic heteroaryl rings such as the 8 to 12 membered bicyclic heteroaryl rings described above, fused tricyclic heteroaryl rings such as the 11 to 14 membered tricyclic heteroaryl rings described above; and fused bicyclic or tricyclic heterocyclyl rings as described above.
[0054] In various embodiments, the substituents are selected from optionally substituted heteroatoms and optionally substituted, optionally hetero-, optionally cyclic C1-C18 hydrocarbon groups, particularly wherein the optionally substituted, optionally hetero-, optionally cyclic C1-C18 hydrocarbon group is optionally substituted, optionally hetero-, optionally cyclic alkyl, alkenyl or alkynyl, or optionally substituted, optionally hetero-aryl; and / or the optionally substituted heteroatom is halogen, optionally substituted hydroxy (e.g. The invention also includes but is not limited to alkyl, alkyl and alkyl groups (e.g., alkyl, alkyloxy, aryloxy), optionally substituted acyl (e.g., formyl, alkanoyl, carbamoyl, carboxyl, acylamino), optionally substituted amino (e.g., amino, alkylamino, dialkylamino, acylamino, sulfonylamino), optionally substituted thiol (e.g., mercapto, alkylthiol, arylthiol), optionally substituted sulfinyl or sulfonyl (e.g., alkylsulfinyl, arylsulfinyl, alkylsulfonyl, arylsulfonyl), nitro, or cyano.
[0055] In various embodiments, the substituents are selected from halogen, -R', -OR', =O, =NR', =N-OR', -NR'R", -SR', -SiR'R"R"', -OC(O)R', -C(O)R', -CO2R', -CONR'R", -OC(O)NR'R", -NR"C(O)R', -NR'-C(O)NR"R"', -NR'-SO2NR"', -NR"C O2R', -NH-C(NH2)=NH, -NR'C(NH2)=NH, -NH-C(NH2)=NR', -S(O)R', -SO2R', -SO2NR'R", -NR"SO2R, -CN and -NO2, -N3, -CH(Ph)2, perfluoro(C1-C4)alkoxy and perfluoro(C1-C4)alkyl, the number of which is from 0 to 3, particularly preferably those having zero, one or two substituents. R', R" and R'"' each independently refers to hydrogen, unsubstituted (C1-C8)alkyl and heteroalkyl, (C1-C8)alkyl and heteroalkyl substituted by 1 to 3 halogens, unsubstituted aryl, aryl substituted by 1 to 3 halogens, unsubstituted alkyl, alkoxy or thioalkoxy groups, or aryl-(C1-C4)alkyl groups. When R' and R" are attached to the same nitrogen atom, they may be combined with the nitrogen atom to form a 5-, 6-, or 7-membered ring. Thus, -NR'R" includes 1-pyrrolidinyl and 4-morpholinyl, "alkyl" includes such groups as trihaloalkyl (e.g., -CF3 and -CH2CF3), and when the aryl group is 1,2,3,4-tetrahydronaphthalene, it may be substituted with a substituted or unsubstituted (C3-C7)spirocycloalkyl group. The (C3-C7)spirocycloalkyl group may be substituted in the same manner as defined herein for "cycloalkyl".
[0056] Preferred substituents are selected from halogen, -R', -OR', =O, -NR'R", -SR', -SiR'R"R"', -OC(O)R', -C(O)R', -CO2R', -CONR'R", -OC(O)NR'R", -NR"C(O)R', -NR"CO2R', -NR'-SO2NR"R"', -S(O)R', -SO2R', -SO2NR'R", -NR"SO2R, -CN and -NO2, perfluoro(C1-C4)alkoxy and perfluoro(C1-C4)alkyl, wherein R' and R" are as defined above.
[0057] Preferred substituents are disclosed herein and exemplified in the tables, structures, examples and claims, and may be applied to different compounds of the invention, ie, the substituents of any given compound may be used combinatorically with other compounds.
[0058] In particular embodiments suitable substituents are independently substituted or unsubstituted heteroatoms, substituted or unsubstituted, 0-3 heteroatoms C1-C6 alkyl, C1-C3 alkyl, or C1-C2 alkyl, substituted or unsubstituted, 0-3 heteroatoms C2-C6 alkenyl, substituted or unsubstituted, 0-3 heteroatoms C2-C6 alkynyl, or substituted or unsubstituted, 0-3 heteroatoms C5-C14 aryl, C6-C14 aryl, or C5-C6 aryl, wherein each heteroatom is independently oxygen, phosphorus, sulfur or nitrogen.
[0059] In a more particular embodiment, suitable substituents are independently aldehyde, aldimine, alkanoyloxy, alkoxy, alkoxycarbonyl, alkoxy, alkyl, alkenyl, alkynyl, amine, azo, halogen, carbamoyl, carbonyl, carboxyl, cyano, ester, haloformyl, peroxyhydroxy, hydroxy, imine, isocyano, isocyanate, N-tert-butoxycarbonyl, nitrate, nitrile, nitrite, nitro, nitroso, phosphate, phosphono, thioether, sulfonyl, sulfo, mercapto, thiol, thiocyano, trifluoromethyl or trifluoromethyl ether (OCF3).
[0060] Combinations of substituents as disclosed herein are those that result in the formation of stable or chemically feasible compounds. As an abbreviation or by convention, some hydrogen atoms attached to an atom (e.g., a carbon atom C or a nitrogen atom N) are not explicitly stated in a chemical structure, formula, or symbol; the hydrogen atoms are considered to be present to the extent that the valence of the atom (e.g., C or N) is completed.
[0061] Compounds may contain asymmetric centers and therefore may exist in the form of enantiomers. When compounds have two or more asymmetric centers, they may additionally exist in the form of diastereomers. Enantiomers and diastereomers belong to the category of wider stereoisomers. All these possible stereoisomers, such as substantially pure resolved enantiomers, racemic mixtures thereof, and mixtures of diastereomers, are intended to be included. It is intended to include all stereoisomers of a compound and / or its pharmaceutically acceptable salt. Unless otherwise specifically mentioned, a reference to an isomer is applicable to any of the possible isomers. When the isomeric composition is not specified, all possible isomers are included.
[0062] The term "substantially pure" means that the target stereoisomer contains no more than 35% by weight, such as no more than 30%, further such as no more than 25%, even further such as no more than 20% of any other stereoisomer. In some embodiments, the term "substantially pure" means that the target stereoisomer contains no more than 10% by weight, for example, no more than 5%, such as no more than 1% of any other stereoisomer.
[0063] When compounds contain olefinic double bonds, unless specified otherwise, such double bonds are meant to include both E and Z geometric isomers.
[0064] Some compounds may have different points of hydrogen attachment, known as tautomers. For example, a compound comprising a carbonyl -CH2C(O)- group (keto form) may undergo tautomerism to form a hydroxyl -CH=C(OH)- group (enol form). Keto and enol forms, singly and as mixtures thereof, are also intended to be included where appropriate.
[0065] It may be advantageous to separate the reaction products from each other and / or from the starting materials. The desired products of each step or series of steps are separated and / or purified (hereinafter separated) to the desired homogeneity by techniques commonly used in the art. Typically, such separations involve multiphase extraction, crystallization from a solvent or solvent mixture, distillation, sublimation, or chromatographic separation. Chromatography can involve many methods, including, for example: reverse phase and normal phase; size exclusion; ion exchange; high pressure, medium pressure and low pressure liquid chromatography methods and apparatus; small scale analysis; simulated moving bed ("SMB") and preparative thin layer or thick layer chromatography, as well as small scale thin layer and flash chromatography techniques. Those skilled in the art will apply the technique most likely to achieve the desired separation.
[0066] By methods well known to those skilled in the art, for example by chromatography and / or fractional crystallization, diastereomeric mixtures can be separated into their single diastereomers according to their physicochemical differences. Enantiomers can be separated by converting enantiomeric mixtures into diastereomeric mixtures by reacting with suitable optically active compounds (e.g. chiral auxiliary agents such as chiral alcohols or Mosher acyl chlorides), separating diastereomers and converting (e.g. hydrolyzing) single diastereomers into corresponding pure enantiomers. Enantiomers can also be separated by using chiral HPLC columns.
[0067] Individual stereoisomers, e.g., substantially pure enantiomers, can be obtained by resolving the racemic mixture using methods such as the formation of diastereoisomers using optically active resolving agents. Racemic mixtures of chiral compounds of the invention can be separated and isolated by any suitable method, including: (1) formation of ionic diastereomeric salts with chiral compounds and separation by fractional crystallization or other methods, (2) formation of diastereomeric compounds with chiral derivatizing agents, separation of the diastereoisomers, and conversion to pure stereoisomers, and (3) direct separation of the substantially pure or enriched stereoisomers under chiral conditions.
[0068] "Pharmaceutically acceptable salts" include, but are not limited to, salts with inorganic acids, for example, selected from hydrochlorides, phosphates, diphosphates, hydrobromides, sulfates, sulfinates, and nitrates; and salts with organic acids, for example, selected from malate, maleate, fumarate, tartrate, succinate, citrate, lactate, methanesulfonate, p-toluenesulfonate, 2-hydroxyethylsulfonate, benzoate, salicylate, stearate, alkanecarboxylates such as acetate, and salts with HOOC-(CH2)n-COOH, wherein n is selected from 0 to 4. Similarly, examples of pharmaceutically acceptable cations include, but are not limited to, sodium, potassium, calcium, aluminum, lithium, and ammonium.
[0069] In addition, if the compound is obtained in the form of an acid addition salt, the free base can be obtained by alkalizing a solution of the acid salt. In contrast, if the product is a free base, an addition salt, such as a pharmaceutically acceptable addition salt, can be prepared by dissolving the free base in a suitable organic solvent and treating the solution with an acid according to conventional methods for preparing acid addition salts from basic compounds. Those skilled in the art will recognize that a variety of synthetic methods can be used to prepare non-toxic pharmaceutically acceptable addition salts without undue experimentation.
[0070] "Treating", "treat" or "treatment" refers to the administration of at least one compound and / or at least one stereoisomer thereof, and / or at least one hydrate thereof, and / or at least one pharmaceutically acceptable salt thereof to a subject in recognized need thereof.
[0071] "Effective amount" refers to an amount of at least one compound and / or at least one of its stereoisomers, and / or at least one hydrate thereof, and / or at least one pharmaceutically acceptable salt thereof, which is effective to "treat" the disease or disorder of the subject and will cause the biological or medical response of the tissue, system, animal or human to a certain extent, such as when administered, sufficient to prevent the development of one or more of the symptoms of the condition or disorder being treated or to alleviate them to a certain extent. The therapeutically effective amount will vary depending on the compound, the disease and its severity as well as the age, weight, etc. of the mammal to be treated.
[0072] The term "at least one substituent" includes, for example, 1-4, such as 1-3, further such as 1 or 2 substituents. For example, "at least one substituent R16" herein includes 1-4, such as 1-3, further such as 1 or 2 substituents selected from the R16 list as described herein.
[0073] The subject compound and its stereoisomer, its hydrate and its pharmaceutically acceptable salt can be used alone or in combination with at least one other therapeutic agent for treatment. In some embodiments, the compound, its stereoisomer, its hydrate and its pharmaceutically acceptable salt can be used in combination with at least one other therapeutic agent. The compound disclosed herein and / or a pharmaceutically acceptable salt can be administered in a single dosage form or in a separate dosage form with at least one other therapeutic agent. When administered in separate dosage forms, at least one other therapeutic agent can be administered before, simultaneously or after administering the compound disclosed herein and / or a pharmaceutically acceptable salt.
[0074] Also provided is a composition comprising the subject compound and its stereoisomers, hydrates thereof and / or pharmaceutically acceptable salts thereof, and at least one pharmaceutically acceptable carrier.
[0075] Compositions comprising subject compounds and stereoisomers thereof, hydrates thereof and / or pharmaceutically acceptable salts thereof can be given in various known ways, for example, orally, topically, rectally, parenterally, by inhalation spray or by implanted reservoirs, although in any given case, the most suitable approach will depend on the specific host, and the nature and severity of the condition to which the active ingredient being given is directed. The term "parenteral" as used herein includes subcutaneous, intradermal, intravenous, intramuscular, intraarticular, intraarterial, intrasynovial, intrasternal, intrathecal, intralesional and intracranial injection or infusion techniques. Compositions disclosed herein can conveniently exist in unit dosage form and be prepared by any method well known in the art.
[0076] The subject compound and its stereoisomer, its hydrate and its pharmaceutically acceptable salt can be administered orally in the form of solid dosage forms such as capsules, tablets, lozenges, dragees, granules and powders or in the form of liquid dosage forms such as elixirs, syrups, emulsions, dispersions and suspensions. The subject compound disclosed herein and its stereoisomer, its hydrate and / or its pharmaceutically acceptable salt can also be administered parenterally in the form of sterile liquid dosage forms, such as dispersions, suspensions or solutions. Other dosage forms that can also be used to administer the subject compound disclosed herein and its stereoisomer, its hydrate and / or its pharmaceutically acceptable salt are in the form of ointments, creams, drops, transdermal patches or powders for topical administration, in the form of ophthalmic solutions or suspension preparations for eye administration, i.e., eye drops, in the form of aerosol sprays or powder compositions for inhalation or intranasal administration, or in the form of creams, ointments, sprays or suppositories for rectal or vaginal administration.
[0077] Gelatin capsules containing the compounds disclosed herein and / or at least one pharmaceutically acceptable salt thereof and powdered carriers such as lactose, starch, cellulose derivatives, magnesium stearate, stearic acid, etc. can also be used. Similar diluents can be used to prepare compressed tablets. Both tablets and capsules can be made into sustained release products to continuously release the drug over a period of time. Compressed tablets can be coated with sugar or film to cover any unpleasant taste and protect the tablet from atmospheric influences, or enteric coating to selectively disintegrate in the gastrointestinal tract.
[0078] Liquid dosage forms for oral administration may further comprise at least one agent selected from coloring agents and flavoring agents to increase patient acceptance.
[0079] In general, water, suitable oil, saline, aqueous dextrose (glucose) and related sugar solutions and glycols such as propylene glycol or polyethylene glycol can be examples of suitable carriers for parenteral solutions. The solution for parenteral administration can include a water-soluble salt of at least one compound described herein, at least one suitable stabilizer and, if necessary, at least one buffer substance. Antioxidants such as sodium bisulfite, sodium sulfite or ascorbic acid, alone or in combination, can be examples of suitable stabilizers. Citric acid and salts thereof and sodium EDTA can also be used as examples of suitable stabilizers. In addition, parenteral solutions can further include at least one preservative, for example, selected from benzalkonium chloride, methylparaben and propylparaben and chlorobutanol.
[0080] Pharmaceutically acceptable carriers are, for example, selected from carriers that are compatible with the active ingredient of the composition (and, in some embodiments, capable of stabilizing the active ingredient) and harmless to the subject to be treated. For example, solubilizers, such as cyclodextrins (which can form specific, more soluble complexes with at least one compound disclosed herein and / or at least one pharmaceutically acceptable salt), can be used as pharmaceutical excipients for delivering the active ingredient. Examples of other carriers include colloidal silicon dioxide, magnesium stearate, cellulose, sodium lauryl sulfate, and pigments such as D&C Yellow #10. Suitable pharmaceutically acceptable carriers are described in Remington's Pharmaceutical Sciences, A. Osol, which is a standard reference text in the art.
[0081] For suction giving, theme compound and its stereoisomer, its hydrate and / or its pharmaceutically acceptable salt can be conveniently delivered with the form presented by the aerosol spray from the packaging of pressurization or atomizer. Theme compound and its stereoisomer, its hydrate and its pharmaceutically acceptable salt can also be delivered in powder form, and it can be prepared and powder composition can be sucked by means of blowing into powder inhaler device. A kind of exemplary delivery system for suction can be metered dose inhalation (MDI) aerosol, and it can be formulated as the suspension or solution of theme compound disclosed herein and its stereoisomer, its hydrate and / or its pharmaceutically acceptable salt / at least one suitable propellant (selected from for example fluorocarbon and hydrocarbon).
[0082] For ocular administration, ophthalmic preparations can be formulated as solutions or suspensions of the subject compound and its stereoisomers, its hydrates, and / or its pharmaceutically acceptable salts in appropriate weight percentages in an appropriate ophthalmic vehicle such that the subject compound and its stereoisomers, its hydrates, and / or at least one pharmaceutically acceptable salt thereof remain in contact with the ocular surface for a sufficient period of time to allow the compound to penetrate the cornea and internal areas of the eye.
[0083] Useful pharmaceutical dosage forms for administering the subject compounds disclosed herein and stereoisomers thereof, hydrates thereof, and / or pharmaceutically acceptable salts thereof include, but are not limited to, hard and soft gelatin capsules, tablets, parenteral injections, and oral suspensions.
[0084] The dosage administered will depend on a variety of factors, such as the age, health and weight of the recipient, the extent of the disease, the type of concurrent treatment (if any), the frequency of treatment, and the nature of the desired effect. In general, the daily dose of the active ingredient may vary, for example, from 0.1 to 2000 mg per day. For example, 10-500 mg, once or more per day, may be effective to obtain the desired results.
[0085] In some embodiments, a plurality of unit capsules can be prepared by filling each standard two-piece hard gelatin capsule with, for example, 100 mg of a powdered form of the subject compound disclosed herein and its stereoisomers, hydrates thereof, and / or pharmaceutically acceptable salts thereof, 150 mg of lactose, 50 mg of cellulose, and 6 mg of magnesium stearate.
[0086] In some embodiments, a mixture of the compound, its stereoisomer, its hydrate, and / or its pharmaceutically acceptable salt with a digestible oil such as soybean oil, cottonseed oil, or olive oil can be prepared and injected into gelatin by a positive displacement pump to make soft gelatin capsules containing 100 mg of the active ingredient. The capsules are washed and dried.
[0087] In some embodiments, a large number of tablets can be prepared by conventional procedures so that the dosage unit contains, for example, 100 mg of the compound, its stereoisomer, its hydrate, and / or its pharmaceutically acceptable salt, 0.2 mg of colloidal silicon dioxide, 5 mg of magnesium stearate, 275 mg of microcrystalline cellulose, 11 mg of starch and 98.8 mg of lactose. Appropriate coatings may be used to increase palatability or delay absorption.
[0088] In some embodiments, a parenteral composition suitable for administration by injection can be prepared by stirring 1.5% by weight of a compound disclosed herein and / or at least an enantiomer, diastereomer, or pharmaceutically acceptable salt thereof in 10% by volume propylene glycol. The solution is made up to the desired volume with water for injection and sterilized.
[0089] In some embodiments, an aqueous suspension can be prepared for oral administration. For example, 5 ml of an aqueous suspension containing 100 mg of a finely divided compound, a stereoisomer thereof, a hydrate thereof, and / or a pharmaceutically acceptable salt thereof, 100 mg of sodium carboxymethylcellulose, 5 mg of sodium benzoate, 1.0 g of sorbitol solution, USP, and 0.025 ml of vanillin can be used.
[0090] When the compound, its stereoisomer, its hydrate, and / or its pharmaceutically acceptable salt is administered in steps or in combination with at least one other therapeutic agent, the same dosage form can usually be used. When the drug is administered in a physical combination, the dosage form and administration route should be selected according to the compatibility of the combined drugs. Therefore, the term co-administration is understood to include the simultaneous or sequential administration of at least two medicaments, or alternatively, the administration of a fixed dose combination of at least two active ingredients.
[0091] The compounds disclosed herein, their stereoisomers, their hydrates, and / or their pharmaceutically acceptable salts may be administered as the sole active ingredient or in combination with at least one second active ingredient.
[0092] The subject compound, its stereoisomer, its hydrate, and / or pharmaceutically acceptable salt are incorporated into a pharmaceutical composition or preparation. The composition will include a pharmaceutically acceptable diluent and / or carrier, that is, a diluent or carrier that is physiologically compatible and substantially free of pathogenic impurities. Suitable excipients or carriers and methods for preparing compositions that can be given are known or apparent to those skilled in the art, and are described in more detail in publications such as Remington's Pharmaceutical Science, Mack Publishing Co, NJ (1991). The composition can also be in the form of controlled release or sustained release compositions as known in the art. For many applications, for morning / daytime dosing, the subject compound, its stereoisomer, its hydrate, and / or pharmaceutically acceptable salt are given, and night is the time of inactivity.
[0093] The subject compound, its stereoisomer, its hydrate, and / or pharmaceutically acceptable salt can be used in the form of itself or its pharmaceutically acceptable salt, such as hydrochloride, hydrobromide, acetate, sulfate, citrate, carbonate, trifluoroacetate, etc. When the compound contains a relatively acidic functional group, the salt can be obtained by adding the required base (neat or in a suitable inert solvent). Examples of pharmaceutically acceptable base addition salts include sodium salts, potassium salts, calcium salts, ammonium salts, organic amino salts or magnesium salts, etc. When the compound contains a relatively basic functional group, the salt can be obtained by adding the required acid (neat or in a suitable inert solvent). Examples of pharmaceutically acceptable acid addition salts include those derived from inorganic acids such as hydrochloric acid, hydrobromic acid, nitric acid, carbonic acid, monohydrogencarbonic acid, phosphoric acid, monohydrogenphosphoric acid, dihydrogenphosphoric acid, sulfuric acid, monohydrogensulfuric acid, hydroiodic acid, or phosphorous acid, and those derived from relatively nontoxic organic acids such as acetic acid, propionic acid, isobutyric acid, maleic acid, malonic acid, benzoic acid, succinic acid, suberic acid, fumaric acid, lactic acid, mandelic acid, phthalic acid, benzenesulfonic acid, p-toluenesulfonic acid, citric acid, tartaric acid, methanesulfonic acid, etc. Also included are salts of amino acids such as arginine salts, and salts of organic acids such as glucuronic acid or galacturonic acid, etc. (see, e.g., Berge et al., "Pharmaceutical Salts", Journal of Pharmaceutical Science, 1977, 66, 1-19).
[0094] The neutral form of the compound can be regenerated by contacting the salt with a base or acid and isolating the parent compound in a conventional manner. The parent form of the compound differs from the various salt forms in certain physical properties, such as solubility in polar solvents, but in other respects, for the purposes of the present invention, the salt is equivalent to the parent form of the compound.
[0095] In addition to the salt form, the present invention also provides compounds in the form of prodrugs. The prodrugs of the compounds described herein are those compounds that are easily chemically changed under physiological conditions to provide the compounds of the present invention. In addition, the prodrug can be converted into the compounds of the present invention by chemical or biochemical methods in an ex vivo environment. For example, when the prodrug is placed in a transdermal patch reservoir with a suitable enzyme or chemical reagent, the prodrug can be slowly converted into the compounds of the present invention. Prodrugs are generally useful because, in some cases, they may be easier to give than the parent drug. For example, their bioavailability by oral administration may be higher than that of the parent drug. The solubility of the prodrug in the pharmacological composition may also be better than that of the parent drug. A variety of prodrug derivatives are known in the art, such as those that rely on the hydrolytic cleavage or oxidative activation of the prodrug. In the absence of limitation, an example of a prodrug is a compound of the present invention, which is given in the form of an ester ("prodrug"), but then metabolically hydrolyzed into a carboxylic acid, an active entity.
[0096] Some compounds of the present invention may exist in non-solvated form as well as solvated form, including hydrated form. Generally speaking, solvated form is equivalent to non-solvated form and is intended to be included within the scope of the present invention. Some compounds of the present invention may exist in multiple crystallized or amorphous forms. Generally speaking, all physical forms are equivalent for the intended application of the present invention, and are intended to be within the scope of the present invention.
[0097] Some of the subject compounds, stereoisomers, hydrates, and / or pharmaceutically acceptable salts thereof possess asymmetric carbon atoms (optical centers) or double bonds; the racemates, diastereomers, geometric isomers and individual isomers are all intended to be encompassed within the scope of the present invention.
[0098] The compounds of the present invention may also contain unnatural proportions of atomic isotopes, such as deuterium, such as -CD3, CD2H or CDH2, which replace methyl, on one or more atoms constituting such compounds. For example, the compounds may be radiolabeled with radioactive isotopes, such as tritium (3H), iodine 125 (125I) or carbon 14 (14C). All isotopic variations of the compounds of the present invention, whether radioactive or not, are intended to be included within the scope of the present invention.
[0099] These compounds are generally administered in a "therapeutically effective amount," i.e., an amount of the subject compound that will elicit the biological or medical response of a tissue, system, animal or human that is being sought by the researcher, veterinarian, medical doctor or other clinician. The term "therapeutically effective amount" includes an amount of the compound that, when administered, is sufficient to prevent the development of, or alleviate to some extent, one or more symptoms of the condition or disorder being treated. The therapeutically effective amount will vary depending on the compound, the disease and its severity, and the age, weight, etc., of the mammal to be treated.
[0100] Contact is generally achieved by administering to the subject an effective amount of one or more compounds of Formula I (supra), including the various embodiments described above. Administration is generally adjusted to achieve a therapeutic dose of about 0.1 to 50, preferably 0.5 to 10, more preferably 1 to 10 mg / kg, although the optimal dose is compound-specific and is generally determined empirically for each compound.
[0101] The term "unit dosage form" refers to a physically discrete unit suitable as a unit dose for human subjects and other mammals, each unit containing a predetermined amount of active substances calculated to produce the desired therapeutic effect, and a suitable pharmaceutical excipient. Typical unit dosage forms include pre-filled, pre-measured ampoules or syringes of liquid compositions, or pills, tablets, capsules, lozenges, etc. in the case of solid compositions. In such compositions, the simulant is usually a minor component (about 0.1 to about 50% by weight or preferably about 1 to about 40% by weight), and the rest are various vehicles or carriers and processing aids that help form the desired dosage form. The unit dosage formulation is preferably about 5, 10, 25, 50, 100, 250, 500 or 1000 milligrams per unit. In a particular embodiment, the unit dosage form is packaged in a multipack suitable for continuous use, such as a blister pack of at least 6, 9 or 12 unit dosage forms including several sheets.
[0102] The subject composition can also be co-formulated and / or co-administered with different compounds to treat applicable indications, or to treat programmed cell death. In various embodiments, applicable indications include brain injury, neurodegenerative diseases, viral infections, immune tolerance and cancer, such as promoting tumor immunity in pancreatic cancer and melanoma.
[0103] In one aspect, the present invention provides a compound of formula Ia:
[0104]
[0105] R1 is C6 aryl including 0 or 1 N heteroatoms, optionally substituted at C3 and / or C5 by halogen or CN;
[0106] R2 is C6 aryl including 0, 1 or 2 N heteroatoms, optionally substituted at C4 by halogen or C1-C3 alkoxy;
[0107] Y is O or N;
[0108] When Y is N, m is 2, and yes
[0109] When Y is O, m is 1, and yes
[0110] R3 and R4 are independently H or alkyl or cycloalkyl or -ORs, for example, H or C1-C6 alkyl or cycloalkyl or -ORs, for example H or C1-C3 alkyl or C3-C6 cycloalkyl or -ORs, wherein Rs is C1-C6 alkyl optionally substituted with halogen and C3-C6 cycloalkyl; wherein alkyl and cycloalkyl, or C1-C6 alkyl and cycloalkyl, or C1-C3 alkyl and C3-C6 cycloalkyl are each independently substituted with 0-3 substituents selected from halide / halogen, optionally substituted N, S or O, and optionally substituted hydrocarbon, wherein R3 and R4 may be attached in a heterocycle;
[0111] or a salt, a hydrate or a stereoisomer thereof.
[0112] In one aspect, the present invention provides a compound of formula I:
[0113]
[0114] R1 is C6 aryl including 0 or 1 N heteroatoms, optionally substituted at C3 and / or C5 by F or CN;
[0115] R2 is C6 aryl including 0, 1 or 2 N heteroatoms, optionally substituted at C4 by F;
[0116] R3 and R4 are independently H or C1-C3 alkyl substituted with 0-3 substituents selected from halide / halogen, optionally substituted N, S or O, and optionally substituted hydrocarbyl, wherein R3 and R4 may be attached in a heterocyclic ring;
[0117] or a salt, a hydrate or a stereoisomer thereof.
[0118] In various embodiments: the R3 and R4 substituents are independently C0-C6: aldehyde, aldimine, alkanoyloxy, alkoxy, alkoxycarbonyl, alkoxy, alkyl, alkenyl, alkynyl, amine, azo, halogen, carbamoyl, carbonyl, carboxyl, cyano, ester, haloformyl, peroxyhydroxy, hydroxy, imine, isocyano, isocyanate, N-tert-butoxycarbonyl, nitrate, nitrile, nitrite, nitro, nitroso, phosphate, phosphono, thioether, sulfonyl, sulfo, mercapto, thiol, thiocyano, trifluoromethyl or trifluoromethyl ether (OCF3);
[0119] R2 includes N2, N4 or N2 / N4; or
[0120] Any combination of the above substituents.
[0121] In one embodiment, the present disclosure provides a compound, a salt, a hydrate or a stereoisomer thereof, wherein the compound has the following structural formula II(1):
[0122]
[0123] wherein Rd is selected from H, halogen, and C1-C3 alkoxy; and all other variables not expressly defined herein are as defined in any of the preceding embodiments as appropriate.
[0124] In one embodiment, the present disclosure provides a compound, a salt, a hydrate or a stereoisomer thereof, wherein the compound has the following structural formula II(1)a:
[0125]
[0126] wherein R3 and R4, for each occurrence, are independently selected from: H, C1-C3 alkyl, C3-C6 cycloalkyl, and -O(C1-C3 alkyl), wherein C1-C3 alkyl and C3-C6 cycloalkyl are each optionally substituted with 1-3 groups selected from: halogen, cyano, and 3 to 6 membered heterocyclyl; and all other variables not expressly defined herein are as defined in any of the preceding embodiments as appropriate.
[0127] In one embodiment, the present disclosure provides a compound, a salt, a hydrate or a stereoisomer thereof, wherein the compound has the following structural formula II(1)b:
[0128]
[0129] wherein R5 is optionally substituted by OH; CN; C3-C6 cycloalkyl; 3 to 6 membered heterocyclyl; ORs; -C(=O)NRpRq; -NRpRq; C1-C3 alkyl, optionally substituted by CN, C3-C6 cycloalkyl, 3 to 6 membered heterocyclyl, or -NRpRq; or C1-C3 alkylene, optionally substituted by CN; wherein Rs is C1-C3 alkyl optionally substituted by halogen and C3-C6 cycloalkyl, wherein Rp and Rq are each independently selected from H and C1-C3 alkyl; and all other variables not expressly defined herein are as defined in any of the appropriate preceding embodiments.
[0130] In one embodiment, the present disclosure provides a compound, a salt, a hydrate or a stereoisomer thereof, wherein the compound has the following structural formula II (2):
[0131]
[0132] All other variables not expressly defined herein are as defined in any of the preceding embodiments as appropriate.
[0133] In one embodiment, the present disclosure provides a compound, a salt, a hydrate or a stereoisomer thereof, wherein the compound has the following structural formula II(2)a:
[0134]
[0135] wherein R3 and R4, for each occurrence, are independently selected from: H, C1-C3 alkyl, C3-C6 cycloalkyl, and -O(C1-C3 alkyl), wherein C1-C3 alkyl and C3-C6 cycloalkyl are each optionally substituted with 1-3 groups selected from: halogen, cyano, and 3 to 6 membered heterocyclyl; and all other variables not expressly defined herein are as defined in any of the preceding embodiments as appropriate.
[0136] In one embodiment, the present disclosure provides a compound, a salt, a hydrate or a stereoisomer thereof, wherein the compound has the following structural formula II(2)b:
[0137]
[0138] wherein R5 is optionally substituted by OH; CN; C3-C6 cycloalkyl; 3 to 6 membered heterocyclyl; ORs; -C(=O)NRpRq; -NRpRq; C1-C3 alkyl, optionally substituted by CN, C3-C6 cycloalkyl, 3 to 6 membered heterocyclyl, or -NRpRq; or C1-C3 alkylene, optionally substituted by CN; wherein Rs is C1-C3 alkyl optionally substituted by halogen and C3-C6 cycloalkyl, wherein Rp and Rq are each independently selected from H and C1-C3 alkyl; and all other variables not expressly defined herein are as defined in any of the appropriate preceding embodiments.
[0139] In one embodiment, the present disclosure provides a compound, a salt, a hydrate or a stereoisomer thereof, wherein the compound has the following structural formula III(1):
[0140]
[0141] wherein R2 is a C6 aryl group including 0, 1 or 2 N heteroatoms, optionally substituted by halogen or C1-C3 alkoxy, Rb and Rc are each independently selected from H, halogen, and CN; and all other variables not expressly defined herein are as defined in any of the appropriate preceding embodiments.
[0142] In one embodiment, the present disclosure provides a compound, a salt, a hydrate or a stereoisomer thereof, wherein the compound has the following structural formula III(1)a:
[0143]
[0144] wherein R3 and R4, for each occurrence, are independently selected from: H, C1-C3 alkyl, C3-C6 cycloalkyl, and -O(C1-C3 alkyl), wherein C1-C3 alkyl and C3-C6 cycloalkyl are each optionally substituted with 1-3 groups selected from: halogen, cyano, and 3 to 6 membered heterocyclyl; and all other variables not expressly defined herein are as defined in any of the preceding embodiments as appropriate.
[0145] In one embodiment, the present disclosure provides a compound, a salt, a hydrate or a stereoisomer thereof, wherein the compound has the following structural formula III(1)b:
[0146]
[0147]
[0148] wherein R5 is optionally substituted by OH; CN; C3-C6 cycloalkyl; 3 to 6 membered heterocyclyl; ORs; -C(=O)NRpRq; -NRpRq; C1-C3 alkyl, optionally substituted by CN, C3-C6 cycloalkyl, 3 to 6 membered heterocyclyl, or -NRpRq; or C1-C3 alkylene, optionally substituted by CN; wherein Rs is C1-C3 alkyl optionally substituted by halogen and C3-C6 cycloalkyl, wherein Rp and Rq are each independently selected from H and C1-C3 alkyl; and all other variables not expressly defined herein are as defined in any of the appropriate preceding embodiments.
[0149] In one embodiment, the present disclosure provides a compound, a salt, a hydrate or a stereoisomer thereof, wherein the compound has the following structural formula III(2):
[0150]
[0151] wherein R2 is C6 aryl including 0, 1 or 2 N heteroatoms, optionally substituted by halogen or C1-C3 alkoxy, and Rb is selected from H, halogen, and CN; and all other variables not expressly defined herein are as defined in any of the appropriate preceding embodiments.
[0152] In one embodiment, the present disclosure provides a compound, a salt, a hydrate or a stereoisomer thereof, wherein the compound has the following structural formula III(2)a:
[0153]
[0154] wherein R3 and R4, for each occurrence, are independently selected from: H, C1-C3 alkyl, C3-C6 cycloalkyl, and -O(C1-C3 alkyl), wherein C1-C3 alkyl and C3-C6 cycloalkyl are each optionally substituted with 1-3 groups selected from: halogen, cyano, and 3 to 6 membered heterocyclyl; and all other variables not expressly defined herein are as defined in any of the preceding embodiments as appropriate.
[0155] In one embodiment, the present disclosure provides a compound, a salt, a hydrate or a stereoisomer thereof, wherein the compound has the following structural formula III(2)b:
[0156]
[0157] wherein R5 is optionally substituted by OH; CN; C3-C6 cycloalkyl; 3 to 6 membered heterocyclyl; ORs; -C(=O)NRpRq; -NRpRq; C1-C3 alkyl, optionally substituted by CN, C3-C6 cycloalkyl, 3 to 6 membered heterocyclyl, or -NRpRq; or C1-C3 alkylene, optionally substituted by CN; wherein Rs is C1-C3 alkyl optionally substituted by halogen and C3-C6 cycloalkyl, wherein Rp and Rq are each independently selected from H and C1-C3 alkyl; and all other variables not expressly defined herein are as defined in any of the appropriate preceding embodiments.
[0158] In one embodiment, the present disclosure provides a compound, a salt, a hydrate or a stereoisomer thereof, wherein the compound has the following structural formula IV(1):
[0159]
[0160] wherein Rb and Rc are each independently selected from H, halogen and CN; Rd is selected from H, halogen, and C1-C3 alkoxy; and R3 and R4 are joined to form a 5-membered heterocyclyl substituted with n Re, wherein Re is selected from OH; CN; C3-C6 cycloalkyl; 3 to 6-membered heterocyclyl; ORs; -C(=O)NRpRq; -NRpRq; C1-C3 alkyl, optionally substituted with CN, C3-C6 cycloalkyl, 3 to 6-membered heterocyclyl, or -NRpRq; or C1-C3 alkylene, optionally substituted with CN; wherein Rs is C1-C3 alkyl optionally substituted with halogen and C3-C6 cycloalkyl, wherein Rp and Rq are each independently selected from H and C1-C3 alkyl; and wherein n is 0, 1, or 2; and all other variables not expressly defined herein are as defined in any of the appropriate preceding embodiments.
[0161] In one embodiment, the present disclosure provides a compound, a salt, a hydrate or a stereoisomer thereof, wherein the compound has the following structural formula IV (2):
[0162]
[0163] wherein Rb and Rc are each independently selected from H, halogen and CN; Rd is selected from H, halogen, and C1-C3 alkoxy; and R3 and R4 are joined to form a 4-membered heterocyclyl substituted with n Re, wherein Re is selected from OH; CN; C3-C6 cycloalkyl; 3 to 6-membered heterocyclyl; ORs; -C(=O)NRpRq; -NRpRq; C1-C3 alkyl, optionally substituted with CN, C3-C6 cycloalkyl, 3 to 6-membered heterocyclyl, or -NRpRq; or C1-C3 alkylene, optionally substituted with CN; wherein Rs is C1-C3 alkyl optionally substituted with halogen and C3-C6 cycloalkyl, wherein Rp and Rq are each independently selected from H and C1-C3 alkyl; and wherein n is 0, 1, or 2; and all other variables not expressly defined herein are as defined in any of the appropriate preceding embodiments.
[0164] In one embodiment, the present disclosure provides a compound, a salt, a hydrate or a stereoisomer thereof, wherein the compound has the following structural formula IV (3):
[0165]
[0166] wherein Rb and Rc are each independently selected from H, halogen and CN; Rd is selected from H, halogen, and C1-C3 alkoxy; X is C, N, or O; and R3 and R4 are joined to form a 6-membered heterocyclyl substituted with n Re, wherein Re is selected from OH; CN; C3-C6 cycloalkyl; 3 to 6-membered heterocyclyl; ORs; -C(=O)NRpRq; -NRpRq; C1-C3 alkyl, optionally substituted with CN, C3-C6 cycloalkyl, 3 to 6-membered heterocyclyl, or -NRpRq; or C1-C3 alkylene, optionally substituted with CN; wherein Rs is C1-C3 alkyl optionally substituted with halogen and C3-C6 cycloalkyl, wherein Rp and Rq are each independently selected from H and C1-C3 alkyl; and wherein n is 0, 1, or 2; and all other variables not expressly defined herein are as defined in any of the appropriate preceding embodiments.
[0167] In one embodiment, the present disclosure provides a compound, a salt, a hydrate or a stereoisomer thereof, wherein the compound has the following structural formula IV (4):
[0168]
[0169] wherein Rb and Rc are each independently selected from H, halogen, and CN; Rd is selected from H, halogen, and C1-C3 alkoxy; and wherein R3 and R4, for each occurrence, are independently selected from: H, C1-C3 alkyl, C3-C6 cycloalkyl, and -O(C1-C3 alkyl), wherein C1-C3 alkyl and C3-C6 cycloalkyl are each optionally substituted with 1-3 groups selected from: halogen, cyano, and 3 to 6 membered heterocyclyl; and all other variables not expressly defined herein are as defined in any of the appropriate preceding embodiments.
[0170] In one embodiment, the present disclosure provides a compound, a salt, a hydrate or a stereoisomer thereof, wherein R3 and R4, for each occurrence, are independently selected from: H; C1-C6 alkyl; and C3-C6 cycloalkyl; and -ORs; wherein the C1-C6 alkyl and C3-C6 cycloalkyl of R3 and R4 are each optionally substituted with 1-3 groups selected from: halogen, cyano and 3 to 6 membered heterocyclyl; or
[0171] R3 and R4 are linked to form a 4-6 membered heterocyclyl, which is optionally substituted by: OH; CN; C3-C6 cycloalkyl; 3 to 6 membered heterocyclyl; ORs; -C(=O)NRpRq; -NRpRq; C1-C3 alkyl, optionally substituted by CN, C3-C6 cycloalkyl, 3 to 6 membered heterocyclyl, or -NRpRq; or C1-C3 alkylene, optionally substituted by CN;
[0172] wherein Rs is C1-C6 alkyl optionally substituted by halogen and C3-C6 cycloalkyl;
[0173] Wherein Rp and Rq are each independently selected from H and C1-C6 alkyl;
[0174] And all other variables not expressly defined herein are as defined in any of the preceding embodiments as appropriate.
[0175] In one embodiment, the present disclosure provides a compound, a salt, a hydrate or a stereoisomer thereof, wherein R3 and R4, for each occurrence, are independently selected from: H; C1-C3 alkyl; and C3-C4 cycloalkyl; and -ORs; wherein the C1-C3 alkyl and C3-C4 cycloalkyl of R3 and R4 are each optionally substituted with 1-3 groups selected from: cyano and 3 to 6 membered heterocyclyl; or
[0176] R3 and R4 are linked to form a 4-6 membered heterocyclyl, which is optionally substituted by: OH; CN; C3-C6 cycloalkyl; 3 to 6 membered heterocyclyl; ORs; -C(=O)NRpRq; -NRpRq; C1-C3 alkyl, optionally substituted by CN, C3-C6 cycloalkyl, 3 to 6 membered heterocyclyl, or -NRpRq; or C1-C3 alkylene, optionally substituted by CN;
[0177] wherein Rs is C1-C3 alkyl optionally substituted by halogen and C3-C4 cycloalkyl; and
[0178] wherein Rp and Rq are each independently selected from H and C1-C3 alkyl;
[0179] And all other variables not expressly defined herein are as defined in any of the preceding embodiments as appropriate.
[0180] In one embodiment, the present disclosure provides a compound, a salt, a hydrate or a stereoisomer thereof, wherein R3 and R4, for each occurrence, are independently selected from: H, OH, methyl, ethyl, -CH2CN, -OCH3, And all other variables not expressly defined herein are as defined in any of the preceding embodiments as appropriate.
[0181] In one embodiment, the present disclosure provides a compound, a salt, a hydrate or a stereoisomer thereof, wherein R3 and R4 are linked to form a 4-6 membered heterocyclic group selected from: And all other variables not expressly defined herein are as defined in any of the preceding embodiments as appropriate.
[0182] In one embodiment, the disclosure provides a compound, salt, hydrate or stereoisomer thereof, wherein R1 is optionally substituted with F, Cl, or CN; and R2 is optionally substituted with F, Cl, or -OCH3; and all other variables not expressly defined herein are as defined in any of the preceding embodiments as appropriate.
[0183] In one embodiment, the present disclosure provides a compound, a salt, a hydrate or a stereoisomer thereof, wherein the compound has one of the structural formulas in Table 1.
[0184] Table 1: Active compounds: structures
[0185]
[0186]
[0187]
[0188]
[0189] The cellular RIP1 inhibitory activities of test compounds 1-67 are summarized in Table 2. In Table 2, the activities are provided as follows: +++ = 0.1 nM ≤ EC50 < 100 nM; ++ = 100 nM ≤ EC50 < 1000 nM; + = 1000 nM ≤ EC50 < 10000 nM.
[0190] Table 2: Cell activity; Necrosis or necroptosis inhibitory activity
[0191]
[0192]
[0193] Example 1
[0194] Synthesis of representative compounds
[0195]
[0196] The above intermediate was synthesized and isolated as a racemate. Chiral HPLC separation gave the S-enantiomer of the intermediate with ee%>98%.
[0197] Compound 1: (S)-2-(4-(5-(3,5-difluorophenyl)-4,5-dihydro-1H-pyrazole-1-carbonyl)piperazine-1-yl)-5-fluoropyrimidine-4-carboxylic acid
[0198]
[0199] Note: A drop of: a drop; Step: step; To: to; the same below.
[0200] Step 1: To a solution of ethyl 2-chloro-5-fluoropyrimidine-4-carboxylate (3.5 g, 17.0 mmol) / DMF (0 ml), (5-(3,5-difluorophenyl)-4,5-dihydro-1H-pyrazol-1-yl)(piperazine-1-yl)methanone (5 g, 17.0 mmol) and TEA (3.44 g, 34.0 mmol) were added. The reaction was stirred at 45 ° C for 4 hours. The mixture was purified by flash column chromatography (EtOAc / PE=0% to 10%). 2.2 g of ethyl 2-(4-(5-(3,5-difluorophenyl)-4,5-dihydro-1H-pyrazole-1-carbonyl)piperazine-1-yl)-5-fluoropyrimidine-4-carboxylate was obtained as a yellow solid. Yield: 27.8%.
[0201] LC-MS (m / z) 463.1 (M+H+ ).
[0202] Step 2: To a solution of ethyl 2-(4-(5-(3,5-difluorophenyl)-4,5-dihydro-1H-pyrazole-1-carbonyl)piperazin-1-yl)-5-fluoropyrimidine-4-carboxylate (2.1 g,) / THF (25 ml) was added 1N NaOH (25 ml). The reaction mixture was stirred at 50°C for 2 hours. 1.7 g of (S)-2-(4-(5-(3,5-difluorophenyl)-4,5-dihydro-1H-pyrazole-1-carbonyl)piperazin-1-yl)-5-fluoropyrimidine-4-carboxylic acid was obtained as a yellow solid. Yield: 86.2%.
[0203] LC-MS (m / z) 435.3 (M+H + ).
[0204] 1 H NMR (400MHz, CDCl3) δ (ppm): 8.12 (d, J = 2.2Hz, 1H), 6.65 (t, J = 1.7Hz, 1H), 6.62-6.56 (m, 2H), 6.45 (tt, J = 8.9, 2.3Hz, 1H), 5 .07(dd,J=11.7,9.9Hz,1H),3.70-3.60(m,2H),3.59-3.45(m,4H),3.43-3.32(m,2H),3.14-3.06(m,1H),2.49-2.41(m,1H).
[0205] Compound 2: (S)-2-(4-(5-(3,5-difluorophenyl)-4,5-dihydro-1H-pyrazole-1-carbonyl)piperazine-1-yl)-5-fluoro-N-hydroxypyrimidine-4-carboxamide
[0206]
[0207] Step 1: To a solution of 2-(4-(5-(3,5-difluorophenyl)-4,5-dihydro-1H-pyrazole-1-carbonyl)piperazin-1-yl)-5-fluoropyrimidine-4-carboxylic acid (600 mg, 1.38 mmol) in THF (20 mL) was added a drop of DMF and SOCl2 (822 mg, 6.91 mmol). The reaction was stirred at 0°C to 40°C for 1 hour. The solvent was removed in vacuo and the crude product was used directly in the next step.
[0208] Step 2: To a solution of 2-(4-(5-(3,5-difluorophenyl)-4,5-dihydro-1H-pyrazole-1-carbonyl)piperazin-1-yl)-5-fluoropyrimidine-4-carbonyl chloride (100 mg, 220.8 μmol) in DCM (5 mL) was added DIPEA (5 mL) and hydroxylamine hydrochloride (31 mg, 441.7 μmol) at 0°C under Ar. The reaction mixture was stirred at 20°C for 1 hour. The mixture was purified by reverse phase chromatography. 36 mg of (S)-2-(4-(5-(3,5-difluorophenyl)-4,5-dihydro-1H-pyrazole-1-carbonyl)piperazin-1-yl)-5-fluoro-N-hydroxypyrimidine-4-carboxamide was obtained as a light yellow solid. Yield: 36.3%.
[0209] LC-MS (m / z) 450.1 (M+H + ).
[0210] 1 H NMR (400MHz, DMSO-d6) δ (ppm): 11.35 (s, 1H), 9.34 (brs, 1H), 8.58 (d, J = 2.4Hz, 1H), 7.14-7.06 (m, 2H), 7.02-6.94 (m, 2H), 5.24(dd,J=11.6,9.9Hz,1H),3.84-3.45(m,8H),3.35(ddd,J=18.3,11.7,1.9Hz,1H),2.63(ddd,J=18.3,10.0,1.6Hz,1H).
[0211] Compound 3: (S)-2-(4-(5-(3,5-difluorophenyl)-4,5-dihydro-1H-pyrazole-1-carbonyl)piperazine-1-yl)-5-fluoro-N-methoxypyrimidine-4-carboxamide
[0212]
[0213] The title compound 3 was prepared in 62.1% yield from (S)-2-(4-(5-(3,5-difluorophenyl)-4,5-dihydro-1H-pyrazole-1-carbonyl)piperazin-1-yl)-5-fluoropyrimidine-4-carbonyl chloride according to the procedure outlined for compound 2.
[0214] LC-MS (m / z) 464.1 (M+H + ).
[0215] 1H NMR (400MHz, DMSO-d6) δ (ppm): 11.83 (s, 1H), 8.56 (d, J = 2.3Hz, 1H), 7.14-7.05 (m, 2H), 7.02-6.94 (m, 2H), 5.24 (d d,J=11.6,9.9Hz,1H),3.86-3.45(m,11H),3.35ddd,J=18.3,9.9,1.6Hz,1H),2.63(ddd,J=18.3,9.9,1.6Hz,1H).
[0216] Compound 4: (S)-2-(4-(5-(3,5-difluorophenyl)-4,5-dihydro-1H-pyrazole-1-carbonyl)piperazin-1-yl)-5-fluoro-N-methoxypyrimidine-4-carboxamide
[0217]
[0218] The title compound 4 was prepared in 65.2% yield from (S)-2-(4-(5-(3,5-difluorophenyl)-4,5-dihydro-1H-pyrazole-1-carbonyl)piperazin-1-yl)-5-fluoropyrimidine-4-carbonyl chloride according to the procedure outlined for compound 2.
[0219] LC-MS (m / z) 448.1 (M+H + ).
[0220] 1 H NMR (400MHz, DMSO-d6) δ (ppm): 8.70 (d, J = 4.9Hz, 1H), 8.60 (d, J = 2.8Hz, 1H), 7.17-7.07 (m, 2H), 7.00 (dt, J = 7.0, 2.2Hz, 2H), 5.26 (dd, J=11.6,9.9Hz,1H),3.89-3.48(m,8H),3.37(ddd,J=18.3,9.9,1.6Hz,1H),2.78(d,J=4.8Hz,3H),2.66(ddd,J=18.3,9.9,1.6Hz,1H).
[0221] Compound 5: 2-(4-(5-(3,5-difluorophenyl)-4,5-dihydro-1H-pyrazole-1-carbonyl)piperazin-1-yl)-5-fluoro-N,N-dimethylpyrimidine-4-carboxamide
[0222]
[0223] The title compound 5 was prepared in 56.3% yield from (S)-2-(4-(5-(3,5-difluorophenyl)-4,5-dihydro-1H-pyrazole-1-carbonyl)piperazin-1-yl)-5-fluoropyrimidine-4-carbonyl chloride according to the procedure outlined for compound 2.
[0224] LC-MS (m / z) 462.1 (M+H + ).
[0225] 1 H NMR (400MHz, CDCl3) δ (ppm): 8.26 (d, J = 1.1Hz, 1H), 6.87-6.77 (m, 3H), 6.72-6.66 (m, 1H), 5.33 (dd, J = 11.7, 9.9Hz, 1H), 3.92-3.81 (m, 2H) ,3.81-3.68(m,4H),3.66-3.56(m,2H),3.31(ddd,J=18.3,11.7,1.8Hz,1H),3.12(s,3H),2.96(s,3H),2.68(ddd,J=18.3,9.9,1.6Hz,1H).
[0226] Compound 6: (S)-2-(4-(5-(3,5-difluorophenyl)-4,5-dihydro-1H-pyrazole-1-carbonyl)piperazin-1-yl)-N-ethyl-5-fluoro-N-methylpyrimidine-4-carboxamide
[0227]
[0228] The title compound 6 was prepared in 58.1% yield from (S)-2-(4-(5-(3,5-difluorophenyl)-4,5-dihydro-1H-pyrazole-1-carbonyl)piperazin-1-yl)-5-fluoropyrimidine-4-carbonyl chloride according to the procedure outlined for compound 2.
[0229] LC-MS (m / z) 476.1 (M+H + ).
[0230] 1H NMR (400MHz, CDCl3) δ (ppm): 8.26-8.25 (m, 1H), 6.88-6.78 (m, 3H), 6.69 (tt, J=8.9,2.3Hz,1H),5.33(dd,J=11.7,9.9Hz,1H),3.92-3.81(m,2H),3.80-3. 69(m,4H),3.65-3.54(m,2H),3.37-3.20(m,3H),3.09(s,2H),2.92(s,1H),2 .68(ddd,J=18.3,9.9,1.6Hz,1H),1.29-1.21(m,2H),1.18(t,J=7.1Hz,2H).
[0231] Compound 7: (S)-azetidin-1-yl(2-(4-(5-(3,5-difluorophenyl)-4,5-dihydro-1H-pyrazole-1-carbonyl)piperazin-1-yl)-5-fluoropyrimidin-4-yl)methanone
[0232]
[0233] The title compound 7 was prepared in 69.2% yield from (S)-2-(4-(5-(3,5-difluorophenyl)-4,5-dihydro-1H-pyrazole-1-carbonyl)piperazin-1-yl)-5-fluoropyrimidine-4-carbonyl chloride according to the procedure outlined for compound 2.
[0234] LC-MS (m / z) 474.1 (M+H + ).
[0235] 1 H NMR (400MHz, CDCl3) δ (ppm): 8.30 (d, J=1.9Hz, 1H), 6.89-6.78 (m, 3H), 6.69 (tt, J=8.8, 2.3Hz, 1H), 5.33 (dd, J=11.7, 9.9Hz, 1H), 4.37-4.2 9(m,2H),4.28-4.19(m,2H),3.93-3.56(m,8H),3.32(ddd,J=18.3,11.7,1.8Hz,1H),2.68(ddd,J=18.3,9.9,1.6Hz,1H),2.43-2.29(m,2H).
[0236] Compound 8: (S)-(5-(3,5-difluorophenyl)-4,5-dihydro-1H-pyrazol-1-yl)(4-(5-fluoro-4-(pyrrolidine-1-carbonyl)pyrimidin-2-yl)piperazin-1-yl)methanone
[0237]
[0238] The title compound 8 was prepared in 73.5% yield from (S)-2-(4-(5-(3,5-difluorophenyl)-4,5-dihydro-1H-pyrazole-1-carbonyl)piperazin-1-yl)-5-fluoropyrimidine-4-carbonyl chloride according to the procedure outlined for compound 2.
[0239] LC-MS (m / z) 488.1 (M+H + ).
[0240] 1 H NMR (400MHz, CDCl3) δ (ppm): 8.30 (d, J=1.9Hz, 1H), 6.89-6.78 (m, 3H), 6.69 (tt, J=8.8, 2.3Hz, 1H), 5.33 (dd, J=11.7, 9.9H z,1H),4.37-4.29(m,2H),4.28-4.19(m,2H),3.93-3.56(m,12H),3.37-3.34(m,1H),2.73-2.63(m,1H),1.99-1.91(m,4H).
[0241] Compound 9: (S)-N-cyclopropyl-2-(4-(5-(3,5-difluorophenyl)-4,5-dihydro-1H-pyrazole-1-carbonyl)piperazin-1-yl)-5-fluoro-N-methylpyrimidine-4-carboxamide
[0242]
[0243] The title compound 9 was prepared in 63.7% yield from (S)-2-(4-(5-(3,5-difluorophenyl)-4,5-dihydro-1H-pyrazole-1-carbonyl)piperazin-1-yl)-5-fluoropyrimidine-4-carbonyl chloride according to the procedure outlined for compound 2.
[0244] LC-MS (m / z) 488.1 (M+H + ).
[0245] 1H NMR (400MHz, CDCl3) δ (ppm): 8.25 (d, J = 1.9 Hz, 1H), 6.87-6.78 (m, 3H), 6.69 (tt, J = 8.9 ,2.3Hz,1H),5.32(dd,J=11.7,9.9Hz,1H),3.90-3.82(m,2H),3.80-3.70(m,4H),3.66 -3.57(m,2H),3.31(ddd,J=18.3,11.7,1.8Hz,1H),3.11(s,3H),2.81-2.75(m,1H),2.68(ddd,J=18.2,9.9,1.6Hz,1H),0.64-0.55(m,4H).
[0246] Compound 10: (5-(3,5-difluorophenyl)-4,5-dihydro-1H-pyrazol-1-yl)(4-(5-fluoro-4-(3-(pyrrolidin-1-ylmethyl)azetidine-1-carbonyl)pyrimidin-2-yl)piperazin-1-yl)methanone
[0247]
[0248] The title compound 10 was prepared in 63.7% yield from (S)-2-(4-(5-(3,5-difluorophenyl)-4,5-dihydro-1H-pyrazole-1-carbonyl)piperazin-1-yl)-5-fluoropyrimidine-4-carbonyl chloride according to the procedure outlined for compound 2.
[0249] LC-MS (m / z) 557.2 (M+H + ).
[0250] 1 H NMR (400MHz, CDCl3) δ (ppm): 8.30 (d, J = 2.0Hz, 1H), 6.88-6.77 (m, 3H), 6.68 (tt, J = 8.8, 2.3H z,1H),5.33(dd,J=11.7,9.9Hz,1H),4.57(t,J=8.6Hz,1H),4.36(dd,J=10.8,7.8Hz,1H),4.1 9(dd,J=9.8,4.7Hz,1H),3.96-3.56(m,9H),3.31(ddd,J=18.3,11.8,1.8Hz,1H),3.19-3.17 (m,3H),3.00-2.93(d,J=28.0Hz,4H),2.68(ddd,J=18.3,9.8,1.6Hz,1H),2.01-1.97(m,4H).
[0251] Compound 11: (S)-2-(4-(5-(3,5-difluorophenyl)-4,5-dihydro-1H-pyrazole-1-carbonyl)piperazin-1-yl)-N-ethyl-5-fluoro-N-hydroxypyrimidine-4-carboxamide
[0252]
[0253] The title compound 11 was prepared in 43.5% yield from (S)-2-(4-(5-(3,5-difluorophenyl)-4,5-dihydro-1H-pyrazole-1-carbonyl)piperazin-1-yl)-5-fluoropyrimidine-4-carbonyl chloride according to the procedure outlined for compound 2.
[0254] LC-MS (m / z) 478.1 (M+H + ).
[0255] 1 H NMR (400MHz, CDCl3) δ (ppm): 8.72 (d, J = 1.8Hz, 1H), 7.27-7.16 (m, 3H), 7.09 (tt, J = 9.1, 2.4Hz, 1H), 5.72 (dd, J = 11.7, 10.0Hz ,1H),4.33-3.94(m,8H),3.79-3.63(m,1H),3.15-3.00(m,1H),2.12-1.96(br,1H),1.78-1.67(m,2H),1.63(t,J=7.0Hz,3H).
[0256] Compound 12: (S)-(3,3-difluoroazetidine-1-yl)(2-(4-(5-(3,5-difluorophenyl)-4,5-dihydro-1H-pyrazole-1-carbonyl)piperazine-1-yl)-5-fluoropyrimidin-4-yl)methanone
[0257]
[0258] The title compound 12 was prepared in 39.2% yield from (S)-2-(4-(5-(3,5-difluorophenyl)-4,5-dihydro-1H-pyrazole-1-carbonyl)piperazin-1-yl)-5-fluoropyrimidine-4-carbonyl chloride according to the procedure outlined for compound 2.
[0259] LC-MS (m / z) 510.1 (M+H + ).
[0260] 1H NMR (400MHz, CDCl3) δ (ppm): 8.37 (d, J = 2.2Hz, 1H), 6.89-6.79 (m, 3H), 6.70 (tt, J = 8.9, 2.3Hz, 1H), 5.34 (dd, J = 11.7, 10.0Hz, 1H), 4.73 (td, J =11.8,1.4Hz,2H),4.50(td,J=11.8,1.4Hz,2H),3.90-3.59(m,8H),3.33(ddd,J=18.3,11.8,1.8Hz,1H),2.69(ddd,J=18.3,9.8,1.6Hz,1H).
[0261] Compound 13: (5-(3,5-difluorophenyl)-4,5-dihydro-1H-pyrazol-1-yl)(4-(5-fluoro-4-(3-hydroxyazetidine-1-carbonyl)pyrimidin-2-yl)piperazin-1-yl)methanone
[0262]
[0263] The title compound 13 was prepared in 67.3% yield from (S)-2-(4-(5-(3,5-difluorophenyl)-4,5-dihydro-1H-pyrazole-1-carbonyl)piperazin-1-yl)-5-fluoropyrimidine-4-carbonyl chloride according to the procedure outlined for compound 2.
[0264] LC-MS (m / z) 490.1 (M+H + ).
[0265] 1 H NMR (400MHz, CDCl3) δ (ppm): 8.31 (d, J = 2.0Hz, 1H), 6.88-6.79 (m, 3H), 6.69 (tt ,J=8.9,2.3Hz,1H),5.34(dd,J=11.7,10.0Hz,1H),4.76-4.71(m,1H),4.56-4.5 0(m,1H),4.49-4.41(m,1H),4.26-4.22(m,1H),4.08-4.04(m,1H),3.91-3.56( m, 8H), 3.32 (ddd, J = 18.3, 11.7, 1.8 Hz, 1H), 2.69 ( ddd, J = 18.3, 9.8, 1.6 Hz, 1H).
[0266] Compound 14: (5-(3,5-difluorophenyl)-4,5-dihydro-1H-pyrazol-1-yl)(4-(5-fluoro-4-(2-oxa-6-azaspiro[3.3]heptane-6-carbonyl)pyrimidin-2-yl)piperazin-1-yl)methanone
[0267]
[0268] The title compound 14 was prepared in 42.6% yield from (S)-2-(4-(5-(3,5-difluorophenyl)-4,5-dihydro-1H-pyrazole-1-carbonyl)piperazin-1-yl)-5-fluoropyrimidine-4-carbonyl chloride according to the procedure outlined for compound 2.
[0269] LC-MS (m / z) 516.1 (M+H + ).
[0270] 1 H NMR (400MHz, CDCl3) δ (ppm): 8.32 (d, J = 2.0Hz, 1H), 6.89-6.80 (m, 3H), 6.70 (tt, J = 8.9, 2.3Hz, 1H), 5.34 (dd, J = 11.7, 10.0Hz, 1H), 4.87-4.77 (m ,4H), 4.51(d,J=1.2Hz,2H), 4.35(d,J=1.1Hz,2H), 3.92-3.58(m,8H), 3.33(ddd,J=18.3,11.7,1.8Hz,1H), 2.69(ddd,J=18.3,9.8,1.6Hz,1H).
[0271] Compound 15: (3S)-1-(2-(4-(5-(3,5-difluorophenyl)-4,5-dihydro-1H-pyrazole-1-carbonyl)piperazin-1-yl)-5-fluoropyrimidine-4-carbonyl)pyrrolidine-3-carbonitrile
[0272]
[0273] The title compound 15 was prepared in 63.8% yield from (S)-2-(4-(5-(3,5-difluorophenyl)-4,5-dihydro-1H-pyrazole-1-carbonyl)piperazin-1-yl)-5-fluoropyrimidine-4-carbonyl chloride according to the procedure outlined for compound 2.
[0274] LC-MS (m / z) 513.1 (M+H + ).
[0275] 1H NMR (400MHz, CDCl3) δ (ppm): 8.32 (dd, J=4.5, 1.3Hz, 1H), 6.87-6.77 (m, 3H), 6.69 (tt, J=8.8, 2.3Hz, 1H), 5.34 (dd, J=11.7,10.0Hz,1H),4.10-3.54(m,11H),3.39-3.15(m,2H),2.69(ddd,J=18.3,9.9,1.6Hz,1H),2.48-2.25(m,2H).
[0276] Compound 16: (3R)-1-(2-(4-(5-(3,5-difluorophenyl)-4,5-dihydro-1H-pyrazole-1-carbonyl)piperazin-1-yl)-5-fluoropyrimidine-4-carbonyl)pyrrolidine-3-carbonitrile
[0277]
[0278] The title compound 16 was prepared in 65.3% yield from (S)-2-(4-(5-(3,5-difluorophenyl)-4,5-dihydro-1H-pyrazole-1-carbonyl)piperazin-1-yl)-5-fluoropyrimidine-4-carbonyl chloride according to the procedure outlined for compound 2.
[0279] LC-MS (m / z) 513.1 (M+H + ).
[0280] 1 H NMR (400MHz, CDCl3) δ (ppm): 8.32 (dd, J=4.5, 1.3Hz, 1H), 6.87-6.77 (m, 3H), 6.69 (tt, J=8.8, 2.3Hz, 1H), 5.34 (dd, J=11.7,10.0Hz,1H),4.10-3.54(m,11H),3.39-3.15(m,2H),2.69(ddd,J=18.3,9.9,1.6Hz,1H),2.48-2.25(m,2H).
[0281] Compound 17: (5-(3,5-difluorophenyl)-4,5-dihydro-1H-pyrazol-1-yl)(4-(5-fluoro-4-(piperidine-1-carbonyl)pyrimidin-2-yl)piperazin-1-yl)methanone
[0282]
[0283] The title compound 17 was prepared in 68.2% yield from (S)-2-(4-(5-(3,5-difluorophenyl)-4,5-dihydro-1H-pyrazole-1-carbonyl)piperazin-1-yl)-5-fluoropyrimidine-4-carbonyl chloride according to the procedure outlined for compound 2.
[0284] LC-MS (m / z) 502.1 (M+H + ).
[0285] 1 H NMR (400MHz, CDCl3) δ (ppm): 8.24 (d, J = 1.0Hz, 1H), 6.86-6.78 (m, 3H), 6.69 (tt, J = 8.8, 2.3Hz, 1H), 5.34 (dd, J = 11.7, 10. 0Hz,1H),3.93-3.53(m,12H),3.32(ddd,J=18.3,11.8,1.8Hz,1H),2.68(ddd,J=18.3,9.9,1.6Hz,1H),1.93-1.53(m,6H).
[0286] Compound 18: (5-(3,5-difluorophenyl)-4,5-dihydro-1H-pyrazol-1-yl)(4-(5-fluoro-4-(morpholine-4-carbonyl)pyrimidin-2-yl)piperazin-1-yl)methanone
[0287]
[0288] The title compound 18 was prepared in 61.7% yield from (S)-2-(4-(5-(3,5-difluorophenyl)-4,5-dihydro-1H-pyrazole-1-carbonyl)piperazin-1-yl)-5-fluoropyrimidine-4-carbonyl chloride according to the procedure outlined for compound 2.
[0289] LC-MS (m / z) 504.1 (M+H + ).
[0290] 1 H NMR (400MHz, CDCl3) δ (ppm): 8.27 (d, J=1.0Hz, 1H), 6.87-6.79 (m, 3H), 6.69 (tt, J=8.9, 2.3Hz, 1H), 5.34 (dd, J= 11.7,10.0Hz,1H),3.91-3.54(m,16H),3.32(ddd,J=18.3,11.8,1.8Hz,1H),2.68(ddd,J=18.3,9.9,1.6Hz,1H).
[0291] Compound 19: (5-(3,5-difluorophenyl)-4,5-dihydro-1H-pyrazol-1-yl)(4-(5-fluoro-4-(4-methylpiperazine-1-carbonyl)pyrimidin-2-yl)piperazin-1-yl)methanone
[0292]
[0293] The title compound 19 was prepared in 56.3% yield from (S)-2-(4-(5-(3,5-difluorophenyl)-4,5-dihydro-1H-pyrazole-1-carbonyl)piperazin-1-yl)-5-fluoropyrimidine-4-carbonyl chloride according to the procedure outlined for compound 2.
[0294] LC-MS (m / z) 517.2 (M+H + ).
[0295] 1 H NMR (400MHz, CDCl3) δ (ppm): 8.26 (d, J = 1.0Hz, 1H), 6.88-6.78 (m, 3H), 6.69 (tt, J = 8.9, 2.3Hz, 1H), 5.34 (dd, J = 11.7, 10.0Hz, 1H), 3.91-3. 54(m,12H),3.32(ddd,J=18.3,11.8,1.8Hz,1H),2.68(ddd,J=18.3,9.9,1.6Hz,1H),2.50(t,J=5.1Hz,2H),2.44-2.37(m,2H),2.33(s,3H).
[0296] Compound 20: (S)-2-(4-(5-(3,5-difluorophenyl)-4,5-dihydro-1H-pyrazole-1-carbonyl)piperazin-1-yl)-5-fluoro-N-hydroxy-N-methylpyrimidine-4-carboxamide
[0297]
[0298] The title compound 20 was prepared in 45.8% yield from (S)-2-(4-(5-(3,5-difluorophenyl)-4,5-dihydro-1H-pyrazole-1-carbonyl)piperazin-1-yl)-5-fluoropyrimidine-4-carbonyl chloride according to the procedure outlined for compound 2.
[0299] LC-MS (m / z) 464.1 (M+H + ).
[0300] 1H NMR (400MHz, CDCl3) δ (ppm): 8.31 (dd, J=13.6, 1.3Hz, 1H), 6.88-6.78 (m, 3H), 6.69 (tt, J=8.9, 2.4Hz, 1H), 5.34 (dd, J=11 .7,10.0Hz,1H),3.93-3.58(m,8H),3.41(s,3H),3.32(ddd,J=18.3,11.8,1.8Hz,1H),2.69(ddd,J=18.3,9.9,1.7Hz,1H).
[0301] Compound 21: (S)-(5-(3,5-difluorophenyl)-4,5-dihydro-1H-pyrazol-1-yl)(4-(5-fluoro-4-(3-methoxyazetidine-1-carbonyl)pyrimidin-2-yl)piperazin-1-yl)methanone
[0302]
[0303] The title compound 21 was prepared in 46.1% yield from (S)-2-(4-(5-(3,5-difluorophenyl)-4,5-dihydro-1H-pyrazole-1-carbonyl)piperazin-1-yl)-5-fluoropyrimidine-4-carbonyl chloride according to the procedure outlined for compound 2.
[0304] LC-MS (m / z) 504.1 (M+H + ).
[0305] 1 H NMR (400MHz, CDCl3) δ (ppm): 8.31 (d, J = 2.0Hz, 1H), 6.88-6.78 (m, 3H), 6.69 (tt, J = 8.9, 2.3Hz, 1H), 5.34 (dd, J = 11.7, 10.0Hz, 1H), 4.52-4. 32(m,2H),4.3-4.18(m,2H),4.07(ddd,J=11.1,3.8,1.4Hz,1H),3.93-3.56(m,8H),3.36-3.28(m,4H),2.69(ddd,J=18.3,9.8,1.6Hz,1H).
[0306] Compound 22: (S)-(5-(3,5-difluorophenyl)-4,5-dihydro-1H-pyrazol-1-yl)(4-(5-fluoro-4-(3-methoxy-3-methylazetidine-1-carbonyl)pyrimidin-2-yl)piperazin-1-yl)methanone
[0307]
[0308] The title compound 22 was prepared in 42.5% yield from (S)-2-(4-(5-(3,5-difluorophenyl)-4,5-dihydro-1H-pyrazole-1-carbonyl)piperazin-1-yl)-5-fluoropyrimidine-4-carbonyl chloride according to the procedure outlined for compound 2.
[0309] LC-MS (m / z) 518.1 (M+H + ).
[0310] 1 H NMR (400MHz, CDCl3) δ (ppm): 8.31 (d, J = 2.0Hz, 1H), 6.88-6.78 (m, 3H), 6.69 (tt, J = 8.9, 2.3 Hz,1H),5.34(dd,J=11.7,10.0Hz,1H),4.30(dd,J=9.8,3.6Hz,1H),4.16(d,J=10.8Hz,1H) ,4.04(ddd,J=9.7,3.6,1.5Hz,1H),3.95(dd,J=10.7,1.4Hz,1H),3.90-3.56(m,11H),3.32 (ddd,J=18.3,11.7,1.9Hz,1H), 3.26(d,J=0.4Hz,3H), 2.69(ddd,J=18.3,9.8,1.6Hz,1H).
[0311] Compound 23: (S)-(5-(3,5-difluorophenyl)-4,5-dihydro-1H-pyrazol-1-yl)(4-(4-(3-ethoxyazetidine-1-carbonyl)-5-fluoropyrimidin-2-yl)piperazin-1-yl)methanone
[0312]
[0313] The title compound 23 was prepared in 39.4% yield from (S)-2-(4-(5-(3,5-difluorophenyl)-4,5-dihydro-1H-pyrazole-1-carbonyl)piperazin-1-yl)-5-fluoropyrimidine-4-carbonyl chloride according to the procedure outlined for compound 2.
[0314] LC-MS (m / z) 518.1 (M+H + ).
[0315] 1H NMR (400MHz, CDCl3) δ (ppm): 8.31 (d, J = 2.0Hz, 1H), 6.88-6.78 (m, 3H), 6.69 (tt, J = 8.9 ,2.3Hz,1H),5.34(dd,J=11.7,10.0Hz,1H),4.5-4.43(m,1H),4.41-4.30(m,2H),4.27 -4.19(m,1H),4.13-4.02(m,1H),3.92-3.56(m,8H),3.53-3.39(m,2H),3.32(ddd,J=1 8.3, 11.8, 1.8Hz, 1H), 2.69 (ddd, J=18.3, 9.8, 1.6Hz, 1H), 1.23 (td, J=7.0, 2.5Hz, 3H).
[0316] Compound 24: (S)-(5-(3,5-difluorophenyl)-4,5-dihydro-1H-pyrazol-1-yl)(4-(5-fluoro-4-(3-isopropoxyazetidine-1-carbonyl)pyrimidin-2-yl)piperazin-1-yl)methanone
[0317]
[0318] The title compound 24 was prepared in 45.3% yield from (S)-2-(4-(5-(3,5-difluorophenyl)-4,5-dihydro-1H-pyrazole-1-carbonyl)piperazin-1-yl)-5-fluoropyrimidine-4-carbonyl chloride according to the procedure outlined for compound 2.
[0319] LC-MS (m / z) 532.1 (M+H + ).
[0320] 1 H NMR (400MHz, CDCl3) δ (ppm): 8.30 (d, J = 1.9Hz, 1H), 6.87-6.79 (m, 3H), 6.69 ( tt,J=8.9,2.3Hz,1H),5.33(dd,J=11.7,10.0Hz,1H),4.51-4.34(m,3H),4.26 -4.18(m,1H),4.11-4.02(m,1H),3.92-3.54(m,9H),3.32(ddd,J=18.3,11.7 ,1.8Hz,1H),2.69(ddd,J=18.3,9.8,1.6Hz,1H),1.16(dd,J=8.5,6.1Hz,6H).
[0321] Compound 25: (S)-1-(2-(4-(5-(3,5-difluorophenyl)-4,5-dihydro-1H-pyrazole-1-carbonyl)piperazin-1-yl)-5-fluoropyrimidine-4-carbonyl)azetidine-3-carbonitrile
[0322]
[0323] The title compound 25 was prepared in 56.2% yield from (S)-2-(4-(5-(3,5-difluorophenyl)-4,5-dihydro-1H-pyrazole-1-carbonyl)piperazin-1-yl)-5-fluoropyrimidine-4-carbonyl chloride according to the procedure outlined for compound 2.
[0324] LC-MS (m / z) 499.1 (M+H + ).
[0325] 1 H NMR (400MHz, CDCl3) δ (ppm): 8.36 (d, J = 2.2Hz, 1H), 6.89-6.78 (m, 3H), 6.69 (tt, J = 8.8, 2.3Hz, 1H), 5.33 (dd, J = 11.7, 10.0Hz, 1H), 4.77- 4.67(m,2H),4.56-4.47(m,1H),4.42(dd,J=10.5,6.4Hz,1H),3.89-3.52(m,9H),3.39-3.26(m,1H),2.69(ddd,J=18.3,9.8,1.6Hz,1H).
[0326] Compound 26: (S)-1-(2-(4-((S)-5-(3,5-difluorophenyl)-4,5-dihydro-1H-pyrazole-1-carbonyl)piperazin-1-yl)-5-fluoropyrimidine-4-carbonyl)pyrrolidine-3-carboxamide
[0327]
[0328] The title compound 26 was prepared in 53.6% yield from (S)-2-(4-(5-(3,5-difluorophenyl)-4,5-dihydro-1H-pyrazole-1-carbonyl)piperazin-1-yl)-5-fluoropyrimidine-4-carbonyl chloride according to the procedure outlined for compound 2.
[0329] LC-MS (m / z) 531.1 (M+H + ).
[0330] 1H NMR (400MHz, CDCl3) δ (ppm): 8.28 (d, J=1.2Hz, 1H), 6.89-6.78 (m, 3H), 6.69 (dddt, J=10.4, 8.0, 2.5, 1.3Hz, 1H), 5.65 (br, 1H), 5.50 (br, 1H), 5.33 (dd, J=11.7,9.8Hz,1H),4.07-3.44(m,12H),3.38-3.20(m,1H),3.03(ddd,J=12 .7,8.1,4.7Hz,1H),2.68(ddt,J=18.1,10.0,1.6Hz,1H),2.37-2.12(m,2H).
[0331] Compound 27: (R)-1-(2-(4-((S)-5-(3,5-difluorophenyl)-4,5-dihydro-1H-pyrazole-1-carbonyl)piperazin-1-yl)-5-fluoropyrimidine-4-carbonyl)pyrrolidine-3-carboxamide
[0332]
[0333] The title compound 27 was prepared in 55.2% yield from (S)-2-(4-(5-(3,5-difluorophenyl)-4,5-dihydro-1H-pyrazole-1-carbonyl)piperazin-1-yl)-5-fluoropyrimidine-4-carbonyl chloride according to the procedure outlined for compound 2.
[0334] LC-MS (m / z) 531.1 (M+H + ).
[0335] 1 H NMR (400MHz, CDCl3) δ (ppm): 8.28 (d, J=1.2Hz, 1H), 6.89-6.78 (m, 3H), 6.69 (dddt, J=10.4, 8.0, 2.5, 1.3Hz, 1H), 5.65 (br, 1H), 5.50 (br, 1H), 5.33 (dd, J=11.7,9.8Hz,1H),4.07-3.44(m,12H),3.38-3.20(m,1H),3.03(ddd,J=12 .7,8.1,4.7Hz,1H),2.68(ddt,J=18.1,10.0,1.6Hz,1H),2.37-2.12(m,2H).
[0336] Compound 28: (S)-(5-(3,5-difluorophenyl)-4,5-dihydro-1H-pyrazol-1-yl)(4-(4-(3-((dimethylamino)methyl)azetidine-1-carbonyl)-5-fluoropyrimidin-2-yl)piperazin-1-yl)methanone
[0337]
[0338] The title compound 28 was prepared in 37.6% yield from (S)-2-(4-(5-(3,5-difluorophenyl)-4,5-dihydro-1H-pyrazole-1-carbonyl)piperazin-1-yl)-5-fluoropyrimidine-4-carbonyl chloride according to the procedure outlined for compound 2.
[0339] LC-MS (m / z) 531.2 (M+H + ).
[0340] 1 H NMR (400MHz, CDCl3) δ (ppm): 8.30 (d, J = 1.9Hz, 1H), 6.89-6.77 (m, 3H), 6.69 (tt, J = 8.9, 2.3Hz, 1H), 5.33 (dd, J = 11.7, 9.8Hz, 1H), 4.44 (t, J = 9.0Hz, 1H) ,4.36-4.27(m,1H),3.99(t,J=7.7Hz,1H),3.91-3.55(m,12H),3.32(ddd,J =18.3,11.7,1.8Hz,1H),3.00-2.85(m,1H),2.76-2.62(m,1H),2.31(s,6H).
[0341] Compound 29: (S)-(5-(3,5-difluorophenyl)-4,5-dihydro-1H-pyrazol-1-yl)(4-(5-fluoro-4-(2-azaspiro[3.3]heptane-2-carbonyl)pyrimidin-2-yl)piperazin-1-yl)methanone
[0342]
[0343] The title compound 29 was prepared in 41.5% yield from (S)-2-(4-(5-(3,5-difluorophenyl)-4,5-dihydro-1H-pyrazole-1-carbonyl)piperazin-1-yl)-5-fluoropyrimidine-4-carbonyl chloride according to the procedure outlined for compound 2.
[0344] LC-MS (m / z) 531.2 (M+H + ).
[0345] 1H NMR (400MHz, CDCl3) δ (ppm): 8.29 (d, J = 2.0Hz, 1H), 6.88-6.79 (m, 3H), 6.69 (tt, J = 8.8, 2.3Hz, 1H), 5.33 (dd, J = 11.7, 9.8Hz, 1H), 4.22 (s, 2H), 4.15(s,2H),3.92-3.57(m,8H),3.32(ddd,J=18.3,11.8,1.8Hz,1H),2. 69(ddd,J=18.3,9.9,1.6Hz,1H),2.24-2.14(m,2H),1.26-1.20(m,4H).
[0346] Compound 30: (S)-1-(2-(4-(5-(3,5-difluorophenyl)-4,5-dihydro-1H-pyrazole-1-carbonyl)piperazin-1-yl)-5-fluoropyrimidine-4-carbonyl)azetidine-3-carboxamide
[0347]
[0348] The title compound 30 was prepared in 63.1% yield from (S)-2-(4-(5-(3,5-difluorophenyl)-4,5-dihydro-1H-pyrazole-1-carbonyl)piperazin-1-yl)-5-fluoropyrimidine-4-carbonyl chloride according to the procedure outlined for compound 2.
[0349] LC-MS (m / z) 517.1 (M+H + ).
[0350] 1 H NMR (400MHz, CDCl3) δ (ppm): 8.33 (d, J = 2.1Hz, 1H), 6.88-6.78 (m, 3H), 6.74-6. 64(m,1H),5.79(br,1H),5.64(br,1H),5.33(dd,J=11.7,9.8Hz,1H),4.70-4.6 0(m,1H),4.56-4.51(m,1H),4.43-4.33(m,2H),3.94-3.55(m,8H),3.43-3.40( m, 1H), 3.32 (ddd, J = 18.3, 11.8, 1.8 Hz, 1H), 2.69 ( ddd, J = 18.3, 9.9, 1.6 Hz, 1H).
[0351] Compound 31: ((S)-5-(3,5-difluorophenyl)-4,5-dihydro-1H-pyrazol-1-yl)(4-(4-((S)-3-(dimethylamino)pyrrolidine-1-carbonyl)-5-fluoropyrimidin-2-yl)piperazin-1-yl)methanone
[0352]
[0353] The title compound 31 was prepared in 76.2% yield from (S)-2-(4-(5-(3,5-difluorophenyl)-4,5-dihydro-1H-pyrazole-1-carbonyl)piperazin-1-yl)-5-fluoropyrimidine-4-carbonyl chloride according to the procedure outlined for compound 2.
[0354] LC-MS (m / z) 531.1 (M+H + ).
[0355] 1 H NMR (400MHz, CDCl3) δ (ppm): 8.29 (dd, J = 5.3, 1.3Hz, 1H), 6.86-6.77 (m, 3H), 6. 69(ttd,J=8.9,2.4,1.2Hz,1H),5.33(dd,J=11.7,9.8Hz,1H),4.06-3.44(m,12 H),3.31(ddd,J=18.3,9.9,1.6Hz,1H),2.92-2.83(m,1H),2.68(ddd,J=18.3,9 .9,1.6Hz,1H),2.36(s,3H),2.28(s,3H),2.23-2.15(m,1H),2.02-1.82(m,1H).
[0356] Compound 32: ((S)-5-(3,5-difluorophenyl)-4,5-dihydro-1H-pyrazol-1-yl)(4-(4-((R)-3-(dimethylamino)pyrrolidine-1-carbonyl)-5-fluoropyrimidin-2-yl)piperazin-1-yl)methanone
[0357]
[0358] The title compound 32 was prepared in 78.1% yield from (S)-2-(4-(5-(3,5-difluorophenyl)-4,5-dihydro-1H-pyrazole-1-carbonyl)piperazin-1-yl)-5-fluoropyrimidine-4-carbonyl chloride according to the procedure outlined for compound 2.
[0359] LC-MS (m / z) 531.1 (M+H + ).
[0360] 1H NMR (400MHz, CDCl3) δ (ppm): 8.29 (dd, J = 5.3, 1.3Hz, 1H), 6.86-6.77 (m, 3H), 6. 69(ttd,J=8.9,2.4,1.2Hz,1H),5.33(dd,J=11.7,9.8Hz,1H),4.06-3.44(m,12 H),3.31(ddd,J=18.3,9.9,1.6Hz,1H),2.92-2.83(m,1H),2.68(ddd,J=18.3,9 .9,1.6Hz,1H),2.36(s,3H),2.28(s,3H),2.23-2.15(m,1H),2.02-1.82(m,1H).
[0361] Compound 33: (S)-(5-(3,5-difluorophenyl)-4,5-dihydro-1H-pyrazol-1-yl)(4-(4-(3-(dimethylamino)azetidine-1-carbonyl)-5-fluoropyrimidin-2-yl)piperazin-1-yl)methanone
[0362]
[0363] The title compound 33 was prepared in 75.8% yield from (S)-2-(4-(5-(3,5-difluorophenyl)-4,5-dihydro-1H-pyrazole-1-carbonyl)piperazin-1-yl)-5-fluoropyrimidine-4-carbonyl chloride according to the procedure outlined for compound 2.
[0364] LC-MS (m / z) 517.1 (M+H + ).
[0365] 1 H NMR (400MHz, CDCl3) δ (ppm): 8.26 (dd, J=7.3, 1.0Hz, 1H), 6.87-6.78 (m, 3H), 6.69 (tt, J=8.9, 2.3Hz, 1H), 5.33 (dd, J=11.7, 9.8 Hz,1H),3.94-3.54(m,13H),3.31(ddd,J=18.3,9.9,1.6Hz,1H),3.22(s,3H),2.68(ddd,J=18.3,9.9,1.6Hz,1H),2.31(s,3H).
[0366] Compound 34: (S)-N-(Cyanomethyl)-2-(4-(5-(3,5-difluorophenyl)-4,5-dihydro-1H-pyrazole-1-carbonyl)piperazin-1-yl)-5-fluoro-N-methylpyrimidine-4-carboxamide
[0367]
[0368] The title compound 34 was prepared in 82.4% yield from (S)-2-(4-(5-(3,5-difluorophenyl)-4,5-dihydro-1H-pyrazole-1-carbonyl)piperazin-1-yl)-5-fluoropyrimidine-4-carbonyl chloride according to the procedure outlined for compound 2.
[0369] LC-MS (m / z) 487.1 (M+H + ).
[0370] 1 H NMR (400MHz, CDCl3) δ (ppm): 8.33 (dd, J = 13.1, 1.1 Hz, 1H), 6.89-6.78 (m, 3H), 6.74-6.64 (m, 1H), 5.33 (dd, J = 11.7, 9.8 Hz, 1H), 4. 53(s,2H),3.96-3.57(m,8H),3.32(ddt,J=18.2,11.7,2.1Hz,1H),3.24(s,1H),3.12(s,2H),2.68(ddt,J=18.3,9.9,1.9Hz,1H).
[0371] Compound 35: (S)-2-(4-(5-(3,5-difluorophenyl)-4,5-dihydro-1H-pyrazole-1-carbonyl)piperazin-1-yl)-N-ethylpyrimidine-4-carboxamide
[0372]
[0373] The title compound 35 was prepared in 25.6% yield from (S)-2-(4-(5-(3,5-difluorophenyl)-4,5-dihydro-1H-pyrazole-1-carbonyl)piperazin-1-yl)pyrimidine-4-carboxylic acid according to the procedure outlined for compound 2.
[0374] LC-MS (m / z) 444.1 (M+H + ).
[0375] 1H NMR (400MHz, CDCl3) δ (ppm): δ8.53 (d, J = 4.8 Hz, 1H), 7.70 (brs, 1H), 7.33 (d, J = 4.8H) z,1H),6.82-6.87(m,3H),6.68-6.73(m,1H),5.34(dd,J=10.0,12.0Hz,1H),3.92-3 .98(m,2H),3.77-3.87(m,4H),3.64-3.70(m,2H),3.49(q,J=7.2Hz,2H),3.33(ddd, J=2.0,12.0,13.6Hz,1H),2.70(ddd,J=1.6,9.6,11.2Hz,1H),1.27(t,J=7.2Hz,3H).
[0376] Mass Spectrometry (ESI): m / z C 21 H 23 Calculated value for F2N7O2: 443.5, found: 444.6 [M+H] + .
[0377] Compound 36: (S)-azetidin-1-yl(2-(4-(5-(3,5-difluorophenyl)-4,5-dihydro-1H-pyrazole-1-carbonyl)piperazin-1-yl)pyrimidin-4-yl)methanone
[0378]
[0379] The title compound 36 was prepared in a similar manner to compound 2.
[0380] 1 H NMR (400MHz, CDCl3) δ7.76-7.49(m,1H),6.90-6.49(m,4H),5.48-5.13(m,2H),4.70-4.00(m,8H),3.36(dd, J=18.3,12.5Hz,1H),2.71(dd,J=18.8,6.4Hz,1H),2.38-2.16(m,2H),1.81-1.51(m,2H),1.07-0.64(m,2H).
[0381] Compound 37: (S)-(5-(3,5-difluorophenyl)-4,5-dihydro-1H-pyrazol-1-yl)(4-(4-(3-isopropoxyazetidine-1-carbonyl)pyrimidin-2-yl)piperazin-1-yl)methanone
[0382]
[0383] The title compound 37 was prepared in a similar manner to the preparation of compound 2.
[0384] 1 H NMR (400MHz, CDCl3) δ8.45 (d, J=4.8Hz, 1H), 7.19 (d, J=4.8Hz, 1H), 6.89 -6.76(m,2H),6.72-6.65(m,1H),5.33(dd,J=10,11.6Hz,1H),4.92-4.74(m,1H),4.58-4.45(m,1H),4.46-4.24(m,2H),4.12 -3.99(m,1H),3.96-3.55(m,8H),3.32(ddd,J=18.3,11.7,1.8Hz,1H),2.69(ddd,J=18.3,9.9,1.6Hz,1H),1.21-1.11(m,6H).
[0385] Compound 38: 2-(4-(5-(3,5-difluorophenyl)-4,5-dihydro-1H-pyrazole-1-carbonyl)piperazin-1-yl)pyrimidine-4-carboxamide
[0386]
[0387] Step 1: (S)-(5-(3,5-difluorophenyl)-4,5-dihydro-1H-pyrazol-1-yl)(1H-imidazol-1-yl)methanone (1 g, 3.62 mmol) was dissolved in 30 mL of anhydrous THF and piperazine (6.24 g, 72.4 mmol) was added. The mixture was stirred at 100° C. for 12 h. The mixture was extracted with DCM, washed with brine, dried (Na2SO4), and concentrated to dryness to give the desired product.
[0388] LC-MS (m / z) 295.1 (M+H + ).
[0389] Step 2: To a solution of (S)-(5-(3,5-difluorophenyl)-4,5-dihydro-1H-pyrazol-1-yl)(piperazin-1-yl)methanone (200 mg, 0.680 mmol) / DMF (3 ml) was added 2-chloropyrimidine-4-carboxamide (118 mg, 0.748 mmol). The reaction mixture was stirred at 120°C for 12 hours. The crude product was purified by reverse phase chromatography. 180 mg of the target compound 38 was obtained as a white solid in a yield of 63.8%.
[0390] LC-MS (m / z) 416.1 (M+H + ).
[0391] 1H NMR (400MHz, CDCl3) δ (ppm): 8.55 (d, J = 4.8, 1H), 7.56 (s, 1H), 7.31 (d, J = 4.8, 1H), 6.86-6.81 (m, 3H), 6.72-6.67 (m, 1H), 5.67 (s, 1H), 5.34 (dd, J = 1 1.7,9.8Hz,1H),3.98-3.93(m,2H),3.87-3.76(m,4H),3.68-3.63(m,2H) ,3.33(ddd,J=18.3,11.7,1.8Hz,1H),2.70(ddd,J=18.3,9.8,1.6Hz,1H).
[0392] Compound 39: (S)-6-(4-(5-(3,5-difluorophenyl)-4,5-dihydro-1H-pyrazole-1-carbonyl)piperazin-1-yl)pyrazine-2-carboxamide
[0393]
[0394] To a solution of (S)-(5-(3,5-difluorophenyl)-4,5-dihydro-1H-pyrazol-1-yl)(piperazin-1-yl)methanone (200 mg, 679.6 μmol) / DMF (5 mL) was added 6-chloropyrazine-2-carboxamide (117.7 mg, 747.5 μmol) and CsCO3 (263 mg, 1.36 mmol). The reaction mixture was stirred at 120°C for 12 hours. The crude product was purified by Pre-HPLC. 130 mg of the desired product was obtained as a white solid. Yield: 46.1%.
[0395] LC-MS (m / z) 416.3 (M+H + ).
[0396] 1 H NMR (400MHz, DMSO-d6) δ (ppm): 8.46 (s, 1H), 8.35 (s, 1H), 8.09 (s, 1H), 7.65 (s, 1H), 7.16-7.05 (m, 2H), 6.98 (dt, J=7.0, 2.1Hz, 2H), 5.24 (dd, J=11.6, 9.9Hz, 1H), 3.83-3.47 (m, 8H), 3.35 (ddd, J=18.3, 11.6, 1.9Hz, 1H), 2.64 (ddd, J=18.3, 9.8, 1.6Hz, 1H).
[0397] Compound 40: (S)-6-(4-(5-(3,5-difluorophenyl)-4,5-dihydro-1H-pyrazole-1-carbonyl)piperazin-1-yl)pyrimidine-4-carboxamide
[0398]
[0399] The title compound 40 was prepared in 67.1% yield from 6-chloropyrimidine-4-carboxamide and (S)-(5-(3,5-difluorophenyl)-4,5-dihydro-1H-pyrazol-1-yl)(piperazin-1-yl)methanone according to the procedure outlined for compound 38.
[0400] LC-MS (m / z) 416.1 (M+H + ).
[0401] 1 H NMR (400MHz, DMSO-d6) δ (ppm): 8.62 (d, J = 0.9Hz, 1H), 8.25 (s, 1H), 7.95 (s, 1H), 7.42 (S, 1H), 7.15-7.04 (m, 2H), 7.00-6.97 (m, 2H), 5.24 (dd, J=11.6, 9.9Hz, 1H), 3.86-3.51 (m, 8H), 3.35 (ddd, J=18.4, 11.7, 1.9Hz, 1H), 2.64 (ddd, J=18.4, 9.9, 1.7Hz, 1H).
[0402] Compound 41: (S)-2-(4-(5-phenyl-4,5-dihydro-1H-pyrazole-1-carbonyl)piperazin-1-yl)pyrimidine-4-carboxamide
[0403]
[0404] The title compound 41 was prepared from (S)-(1H-imidazol-1-yl)(5-phenyl-4,5-dihydro-1H-pyrazol-1-yl)methanone according to the procedure outlined for compound 38. Yield: 53.1% for two steps.
[0405] LC-MS (m / z) 380.1 (M+H + ).
[0406] 1 H NMR (400MHz, CDCl3) δ (ppm): 8.54 (d, J = 4.8Hz, 1H), 7.57 (s, 1H), 7.37-7.28 (m, 6H), 6.86 (t, J = 1.7Hz, 1H), 5.63 (s, 1H), 5 .38(dd,J=11.8,9.7Hz,1H),3.98-3.58(m,8H),3.33(ddd,J=18.3,11.8,1.8Hz,1H),2.76(ddd,J=18.3,9.7,1.6Hz,1H).
[0407] Compound 42: (S)-2-(4-(5-(3-cyano-5-fluorophenyl)-4,5-dihydro-1H-pyrazole-1-carbonyl)piperazin-1-yl)pyrimidine-4-carboxamide
[0408]
[0409] The title compound 42 was prepared from (S)-3-(1-(1H-imidazole-1-carbonyl)-4,5-dihydro-1H-pyrazol-5-yl)-5-fluorobenzonitrile according to the procedure outlined for compound 38 in 65.2% yield over two steps.
[0410] LC-MS (m / z) 443.1 (M+H + ).
[0411] 1 H NMR (400MHz, CDCl3) δ (ppm): 8.55 (d, J = 4.8Hz, 1H), 7.57 (s, 1H), 7.42 (t, J = 1.5Hz, 1H), 7.31 (d, J = 4.8Hz, 1H), 7.30-7.21 (m, 2H), 6.91-6.87 (m ,1H),5.67(s,1H),5.37(dd,J=11.7,10.0Hz,1H),4.02-3.59(m,8H),3.36(ddd,J=18.3,11.7,1.8Hz,1H),2.70(ddd,J=18.3,10.0,1.6Hz,1H).
[0412] Compound 43: (S)-2-(4-(5-(5-cyanopyridin-3-yl)-4,5-dihydro-1H-pyrazole-1-carbonyl)piperazin-1-yl)pyrimidine-4-carboxamide
[0413]
[0414] The title compound 43 was prepared from (S)-5-(1-(1H-imidazole-1-carbonyl)-4,5-dihydro-1H-pyrazol-5-yl)nicotinonitrile according to the procedure outlined for compound 38 in 42.6% yield over two steps.
[0415] LC-MS (m / z) 406.1 (M+H + ).
[0416] 1H NMR (400MHz, CDCl3) δ (ppm): 8.80 (dd, J = 3.8, 2.1Hz, 2H), 8.55 (d, J = 4.8Hz, 1H), 7.91 (t, J = 2.1Hz, 1H), 7.56 (s, 1H), 7.32 (d, J = 4.8Hz, 1H), 6.94 (t, J = 1.7Hz,1H),5.64(s,1H),5.42(dd,J=11.7,10.3Hz,1H),4.08-3.52(m,8H) ,3.40(ddd,J=18.2,11.7,1.9Hz,1H),2.75(ddd,J=18.2,10.2,1.6Hz,1H).
[0417] Compound 44: (S)-2-(4-(5-(3,5-difluorophenyl)-4,5-dihydro-1H-pyrazole-1-carbonyl)piperazin-1-yl)pyrimidine-4-carboxylic acid
[0418]
[0419] The title compound 44 was prepared in 76.2% yield from (S)-2-(4-(5-(3,5-difluorophenyl)-4,5-dihydro-1H-pyrazole-1-carbonyl)piperazin-1-yl)-5-fluoropyrimidine-4-carbonyl chloride according to the procedure outlined for compound 38.
[0420] LC-MS (m / z) 417.1 (M+H + ).
[0421] 1 H NMR (400MHz, CDCl3) δ (ppm): δ 8.62 (d, J = 4.8 Hz, 1H), 7.31 (d, J = 4.8 Hz, 1H), 6.87 (t, J = 1.6 Hz, 1H), 6.81-6.84 (m, 2H), 6.68-6.73 (m, 1H), 5.34 (dd, J = 10.0,11.6Hz,1H),3.93-4.00(m,2H),3.78-3.89(m,4H),3.65-3.70(m,2H ), 3.34 (ddd, J=1.6, 11.6, 13.6Hz, 1H), 2.71 (ddd, J=1.6, 9.6, 11.2Hz, 1H).
[0422] Compound 45: (S)-2-(4-(5-(3,5-difluorophenyl)-4,5-dihydro-1H-pyrazole-1-carbonyl)piperazin-1-yl)-N-(2-morpholinoethyl)pyrimidine-4-carboxamide
[0423]
[0424] The title compound 45 was prepared in 32.2% yield from (S)-2-(4-(5-(3,5-difluorophenyl)-4,5-dihydro-1H-pyrazole-1-carbonyl)piperazin-1-yl)pyrimidine-4-carboxylic acid according to the procedure outlined for compound 2.
[0425] Mass Spectrometry (ESI): m / z C 25 H 30 F2N8O3 calculated value 528.6, found value 529.7 [M+H] + .
[0426] 1 H NMR (400MHz, CDCl3) δ (ppm): 8.69 (t, J = 1.2 Hz, 1H), 8.52 (d, J = 4.8 Hz, 1H), 7.18 (d, J =4.8Hz,1H),6.85(t,J=1.6Hz,1H),6.77-6.82(m,2H),6.67-6.73(m,1H),5.31(dd,J= 9.6,11.6Hz,1H),3.78-4.05(m,10H),3.58-3.77(m,6H),3.49(t,J=5.6Hz,2H),3.32( ddd,J=2.0,12.0,13.2Hz,1H),2.92-3.05(m,2H),2.68(ddd,J=1.6,9.6,11.2Hz,1H).
[0427] Compound 46: (S)-2-(4-(5-(3,5-difluorophenyl)-4,5-dihydro-1H-pyrazole-1-carbonyl)piperazin-1-yl)-N-methylpyrimidine-4-carboxamide
[0428]
[0429] The title compound 46 was prepared in 30.4% yield from (S)-2-(4-(5-(3,5-difluorophenyl)-4,5-dihydro-1H-pyrazole-1-carbonyl)piperazin-1-yl)pyrimidine-4-carboxylic acid according to the procedure outlined for compound 2.
[0430] Mass Spectrometry (ESI): m / z C 20 H 21 F2N7O2 calculated value 429.4, found value 430.3 [M+H] + .
[0431] 1H NMR (400MHz, CDCl3) δ (ppm): δ8.51 (d, J = 4.8 Hz, 1H), 7.74 (d, J = 4.4 Hz, 1H), 7.30 (d,J=4.8Hz,1H),6.79-6.85(m,3H),6.66-6.71(m,1H),5.32(dd,J=10.0,11.6H z,1H),3.89-3.96(m,2H),3.74-3.85(m,4H),3.61-3.68(m,2H),3.31(ddd,J=2. 0,11.6,13.6Hz,1H),3.00(d,J=4.2Hz,3H),2.68(ddd,J=1.6,9.6,11.2Hz,1H).
[0432] Compound 47: (S)-2-(4-(5-(3,5-difluorophenyl)-4,5-dihydro-1H-pyrazole-1-carbonyl)piperazin-1-yl)-5-fluoropyrimidine-4-carboxylic acid ethyl ester
[0433]
[0434] (S)-(5-(3,5-difluorophenyl)-4,5-dihydro-1H-pyrazol-1-yl)(piperazine-1-yl)methanone (6 mg, 0.204 mmol) and ethyl 2-chloro-5-fluoropyrimidine-4-carboxylate (38.9 mg, 0.19 mmol) were dissolved in 11.7 ml of DMF. TEA (59 μl) was added. It was stirred at 60° C. under nitrogen for 16 hours. The solvent was evaporated to dryness and purified by preparative TLC (PE / EA=1 / 2) to give 20 mg of 47 as a light yellow solid. Yield: 21.2%.
[0435] Mass Spectrometry (ESI): m / z C 21 H 21 F3N6O3 calculated value 462.4, found value 463.3 [M+H] + .
[0436] 1H NMR (400MHz, CDCl3) δ (ppm): δ8.34 (d, J = 2.0Hz, 1H), 6.78-6.85 (m, 3H), 6.66-6.71 (m, 1H), 5.32 (dd, J = 10.0, 11.2Hz, 1H), 4.43 (q, J = 7.2Hz, 2H), 3.86 -3.91(m,2H),3.72-3.81(m,4H),3.59-3.65(m,2H),3.30(ddd,J=1.6,11. 6, 13.6Hz, 1H), 2.68 (ddd, J=1.6, 10.0, 11.6Hz, 1H), 1.40 (t, J=7.2Hz, 3H).
[0437] Compound 48: (S)-2-(4-(5-(3,5-difluorophenyl)-4,5-dihydro-1H-pyrazole-1-carbonyl)piperazin-1-yl)-5-fluoropyrimidine-4-carboxamide
[0438]
[0439] The title compound 48 was prepared in 66.67% yield from ammonium hydroxide and (S)-2-(4-(5-(3,5-difluorophenyl)-4,5-dihydro-1H-pyrazole-1-carbonyl)piperazin-1-yl)-5-fluoropyrimidine-4-carbonyl chloride according to the procedure outlined for compound 2.
[0440] Mass Spectrometry (ESI): m / z C 19 H 18 F3N7O2 calculated value 433.4, found value 434.3 [M+H] + .
[0441] 1 H NMR (400MHz, CDCl3) δ (ppm): δ 8.40 (d, J = 3.2 Hz, 1H), 7.37 (brs, 1H), 6.80-6.86 (m, 3H), 6.67-6.72 (m, 1H), 5.90 (brs, 1H), 5.33 (dd, J = 10.0, 11 .6Hz,1H),3.86-3.91(m,2H),3.74-3.81(m,4H),3.63-3.67(m,2H),3.32(ddd,J=1.6,11.6,13.6Hz,1H),2.69(ddd,J=1.6,10.0,11.2Hz,1H).
[0442] Compound 49: (S)-2-(4-(5-(3,5-difluorophenyl)-4,5-dihydro-1H-pyrazole-1-carbonyl)piperazin-1-yl)pyrimidine-4-carboxylic acid methyl ester
[0443]
[0444] To a solution of (S)-(5-(3,5-difluorophenyl)-4,5-dihydro-1H-pyrazol-1-yl)(piperazine-1-yl)methanone (500 mg, 1.7 mmol) / DMF (5 ml) was added 2-chloropyrimidine-4-carboxylic acid methyl ester (350 mg, 2.0 mmol) and Et3N (0.7 ml, 5.1 mmol). The resulting mixture was stirred at 45 ° C for 12 hours. After cooling to room temperature. The reaction mixture was poured into water (50 ml) and then extracted with DCM (3×50 ml). The organic layers were combined, dried over anhydrous sodium sulfate, filtered and concentrated under vacuum. The residue was purified by silica gel chromatography (eluted with ethyl acetate / petroleum ether=1:1) to give the title compound as a white solid (500 mg, 68%). Yield: 68%.
[0445] LCMS (ES, m / z): 431.16 [M+H] + .
[0446] 1 H NMR (400MHz, CDCl3) δ8.51(d,J=4.8Hz,1H),7.15(d,J=4.8Hz,1H),6.91-6.78(m,2 H),6.72-6.65(m,1H),5.33(dd,J=11.6,9.9Hz,1H),4.06-3.97(m,2H),3.96(s,3H ),3.88(ddd,J=13.2,7.2,3.4Hz,2H),3.83-3.69(m,2H),3.64(ddd,J=13.2,6.6,3 .4Hz, 2H), 3.32 (ddd, J=18.2, 11.7, 1.8Hz, 1H), 2.69 (ddd, J=18.4, 9.8, 1.6Hz, 1H).
[0447] Compound 50: (S)-(5-(3,5-difluorophenyl)-4,5-dihydro-1H-pyrazol-1-yl)(4-(5-fluoro-4-(3-hydroxy-3-methylazetidine-1-carbonyl)pyrimidin-2-yl)piperazin-1-yl)methanone
[0448]
[0449] To a solution of (S)-2-(4-(5-(3,5-difluorophenyl)-4,5-dihydro-1H-pyrazole-1-carbonyl)piperazin-1-yl)-5-fluoropyrimidine-4-carboxylic acid (50 mg, 115.1 μmol) in DCM (3 mL) was added HATU (66 mg, 172.7 μmol), DIPEA (25 mg, 172.7 μmol) and 3-methylazetidine-3-ol (22 mg, 172.7 μmol). The reaction mixture was stirred at 35 °C for 12 hours. The crude product was purified by reverse phase chromatography. The title compound 50 (26 mg) was obtained as a yellow solid in a yield of 44.9%.
[0450] LC-MS (m / z) 504.1 (M+H + ).
[0451] 1 H NMR (400MHz, CDCl3) δ8.31(d,J=0.7Hz,1H),6.89-6.77(m,3H),6.70(tt,J=8.9,2.4Hz,1H),5.37-5.30(m,1H),4.32(d,J=10.0Hz,1H),4.18( dd,J=9.9,6.4Hz,1H),4.13(s,2H),3.91-3.56(m,8H),3.33(ddd,J=18.3,11.8,1.8Hz,1H),2.69(ddd,J=18.3,9.8,1.6Hz,1H),1.57(s,3H).
[0452] Compound 51: (S)-3-Fluoro-5-(1-(4-(5-fluoro-4-(3-methoxyazetidine-1-carbonyl)pyrimidin-2-yl)piperazine-1-carbonyl)-4,5-dihydro-1H-pyrazol-5-yl)benzonitrile
[0453]
[0454] Step 1: To a solution of 2-(4-(tert-butoxycarbonyl)piperazine-1-yl)-5-fluoropyrimidine-4-carboxylic acid (300 mg, 919.3 μmol) / DCM (10 mL) was added DIPEA (328 mg, 2.76 mmol), HATU (525 mg, 1.38 mmol) and 3-methoxyazetidine (124 mg, 1.01 mmol). The reaction mixture was stirred at 25°C for 12 hours. The mixture was purified by flash chromatography. tert-Butyl 4-(5-fluoro-4-(3-methoxyazetidine-1-carbonyl)pyrimidin-2-yl)piperazine-1-carboxylate was obtained as a yellow solid (310 mg, 85.3%).
[0455] LC-MS (m / z) 396.2 (M+H+ ).
[0456] Step 2: To a solution of tert-butyl 4-(5-fluoro-4-(3-methoxyazetidine-1-carbonyl)pyrimidin-2-yl)piperazine-1-carboxylate (100 mg, 252.89 μmol) in DCM (10 mL) was added TFA (5 mL). The reaction mixture was stirred at 25° C. for 1 hour. The mixture was concentrated under vacuum and used directly in the next step.
[0457] LC-MS (m / z) 296.1 (M+H + ).
[0458] Step 3: To a solution of compound (5-fluoro-2-(piperazin-1-yl)pyrimidin-4-yl)(3-methoxyazetidine-1-yl)methanone (52 mg, 172.5 μmol) / THF (6 ml) was added (S)-3-(1-(1H-imidazole-1-carbonyl)-4,5-dihydro-1H-pyrazol-5-yl)-5-fluorobenzonitrile (50 mg, 172.5 μmol) and Et3N (2 ml). The reaction mixture was stirred at 75°C for 12 hours. The crude product was purified by reverse chromatography. The title compound 51 (63 mg) was obtained as a yellow solid in a yield of 69.9%.
[0459] LC-MS (m / z) 511.1 (M+H + ).
[0460] 1 H NMR(400MHz, CDCl3)δ8.27(d,J=1.9Hz,1H),7.34(t,J=1.5Hz,1H),7.24-7.14(m, 2H),6.84(d,J=1.6Hz,1H),5.60(brs,1H),5.31(dd,J=11.6,9.8Hz,1H),4.44-4.4 0(m,1H),4.33(dd,J=11.2,5.5Hz,1H),4.26-4.11(m,2H),4.05-4.01(m,1H),3.87 -3.50(m,8H),3.35-3.28(m,1H),3.26(s,3H),2.64(ddd,J=18.4,9.7,1.6Hz,1H).
[0461] Compound 52: (S)-(5-Fluoro-2-(4-(5-(5-fluoropyridin-3-yl)-4,5-dihydro-1H-pyrazole-1-carbonyl)piperazin-1-yl)pyrimidin-4-yl)(3-methoxyazetidin-1-yl)methanone
[0462]
[0463] The title compound 52 was prepared according to the procedure outlined for compound 51 from (5-fluoro-2-(piperazin-1-yl)pyrimidin-4-yl)(3-methoxyazetidin-1-yl)methanone.
[0464] LC-MS (m / z) 487.1 (M+H + ).
[0465] 1 H NMR (400MHz, CDCl3) δ8.43(s,1H),8.39(dd,J=2.8,0.9Hz,1H),8.32(dd,J=2.1,1.0H z,1H),7.34(dt,J=9.1,2.6Hz,1H),6.90(s,1H),5.41(t,J=10.9Hz,1H),4.51-4.41( m,1H),4.42-4.32(m,1H),4.32-4.19(m,1H),4.13-4.03(m,1H),3.91-3.56(m,8H),3 .38(ddt,J=18.3,10.3,1.3Hz,1H),3.32(s,3H),2.75(ddt,J=18.3,10.3,1.3Hz,1H).
[0466] Compound 53: (S)-5-(1-(4-(5-fluoro-4-(3-methoxyazetidine-1-carbonyl)pyrimidin-2-yl)piperazine-1-carbonyl)-4,5-dihydro-1H-pyrazol-5-yl)nicotinonitrile
[0467]
[0468] The title compound 53 was prepared according to the procedure outlined for compound 51 from (5-fluoro-2-(piperazin-1-yl)pyrimidin-4-yl)(3-methoxyazetidin-1-yl)methanone.
[0469] LC-MS (m / z) 494.1 (M+H + ).
[0470] 1H NMR (400MHz, CDCl3) δ8.83-8.77(m,2H),8.32(dd,J=1.9,0.7Hz,1H),7.91(t ,J=2.2Hz,1H),6.94(s,1H),5.42(t,J=10.9Hz,1H),4.46(ddd,J=10.4,5.3,3 .1Hz,1H),4.42-4.34(m,1H),4.33-4.18(m,2H),4.08(ddd,J=11.2,3.8,1.3H z,1H),3.91-3.58(m,8H),3.47-3.35(m,1H),3.32(s,3H),2.81-2.68(m,1H).
[0471] Compound 54: (S)-1-(2-(4-(5-(3-cyano-5-fluorophenyl)-4,5-dihydro-1H-pyrazole-1-carbonyl)piperazin-1-yl)-5-fluoropyrimidine-4-carbonyl)azetidine-3-carbonitrile
[0472]
[0473] According to the procedure outlined for compound 51, the title compound 54 was prepared.
[0474] LC-MS (m / z) 506.1 (M+H + ).
[0475] 1 H NMR(400MHz, CDCl3)δ8.31(d,J=2.2Hz,1H),7.33-7.32(m,1H),7.21(d,J=1.4H z,1H),7.19-7.18(m,2H),6.85(s,1H),6.31(brs,1H),5.31(dd,J=11.7,9.6Hz, 1H),4.67(dd,J=7.5,4.3Hz,2H),4.46(t,J=9.9Hz,1H),4.38(dd,J=10.6,6.1Hz ,1H),3.85-3.47(m,8H),3.39-3.25(m,1H),2.64(ddd,J=18.4,9.6,1.5Hz,1H).
[0476] Compound 55: (S)-(5-(3,5-difluorophenyl)-4,5-dihydro-1H-pyrazol-1-yl)(4-(5-fluoro-4-(3-methyleneazetidine-1-carbonyl)pyrimidin-2-yl)piperazin-1-yl)methanone
[0477]
[0478] The title compound 55 was prepared in 69.2% yield from (S)-2-(4-(5-(3,5-difluorophenyl)-4,5-dihydro-1H-pyrazole-1-carbonyl)piperazin-1-yl)-5-fluoropyrimidine-4-carbonyl chloride according to the procedure outlined for compound 2.
[0479] LC-MS (m / z) 486.1 (M+H + ).
[0480] 1 H NMR (400MHz, DMSO-d6) δ8.61(d,J=2.3Hz,1H),7.14-7.07(m,2H),7.05-6.94(m,2H),5.26(dd,J=11.5,10.0Hz,1H),5.10(dt,J=7.8,2.6H z,2H),4.92-4.89(m,2H),4.65-4.63(m,2H),3.79-3.47(m,8H),3.36(ddd,J=18.3,11.6,1.9Hz,1H),2.64(ddd,J=18.3,10.0,1.6Hz,1H).
[0481] Compound 56: (S)-(5-(3,5-difluorophenyl)-4,5-dihydro-1H-pyrazol-1-yl)(4-(5-fluoro-4-(3-methylazetidine-1-carbonyl)pyrimidin-2-yl)piperazin-1-yl)methanone
[0482]
[0483] The title compound 56 was prepared in 72.5% yield from (S)-2-(4-(5-(3,5-difluorophenyl)-4,5-dihydro-1H-pyrazole-1-carbonyl)piperazin-1-yl)-5-fluoropyrimidine-4-carbonyl chloride according to the procedure outlined for compound 2.
[0484] LC-MS (m / z) 488.1 (M+H + ).
[0485] 1H NMR (400MHz, CDCl3) δ8.59(d,J=5.9Hz,1H),7.17(d,J=5.9Hz,1H),7.09(t,J=6.4 Hz,2H),7.00-6.94(m,1H),5.54(td,J=11.0,6.3Hz,1H),4.67(t,J=8.1Hz,1H),4. 50(d,J=8.5Hz,1H),4.18-3.75(m,10H),3.61(ddd,J=18.2,11.7,6.0Hz,1H),3.09 -3.02(m,1H),2.97-2.88(dt,J=17.6,8.1Hz,1H),2.85-2.78(m,1H),1.52(s,3H).
[0486] Compound 57: (S)-2-(1-(2-(4-(5-(3,5-difluorophenyl)-4,5-dihydro-1H-pyrazole-1-carbonyl)piperazin-1-yl)-5-fluoropyrimidine-4-carbonyl)azetidin-3-ylidene)acetonitrile
[0487]
[0488] The title compound 57 was prepared in 63.7% yield from (S)-2-(4-(5-(3,5-difluorophenyl)-4,5-dihydro-1H-pyrazole-1-carbonyl)piperazin-1-yl)-5-fluoropyrimidine-4-carbonyl chloride according to the procedure outlined for compound 2.
[0489] LC-MS (m / z) 511.1 (M+H + ).
[0490] 1 H NMR (400MHz, DMSO-d6) δ8.64 (t, J = 1.9Hz, 1H), 7.16-7.05 (m, 2H), 7.04-6. 94(m,2H),5.94-5.89(m,1H),5.26(t,J=10.7Hz,1H),5.21-5.18(m,1H),5 .16-5.13(m,1H),4.91-4.88(m,1H),4.83-4.81(m,1H),3.80-3.48(m,8H) ,3.36(ddd,J=18.3,11.6,1.8Hz,1H),2.65(ddd,J=18.3,9.9,1.6Hz,1H).
[0491] Compound 58: (S)-2-(1-(2-(4-(5-(3,5-difluorophenyl)-4,5-dihydro-1H-pyrazole-1-carbonyl)piperazin-1-yl)-5-fluoropyrimidine-4-carbonyl)azetidin-3-yl)acetonitrile
[0492]
[0493] The title compound 58 was prepared in 62.1% yield from (S)-2-(4-(5-(3,5-difluorophenyl)-4,5-dihydro-1H-pyrazole-1-carbonyl)piperazin-1-yl)-5-fluoropyrimidine-4-carbonyl chloride according to the procedure outlined for compound 2.
[0494] LC-MS (m / z) 513.1 (M+H + ).
[0495] 1 H NMR (400MHz, DMSO-d6) δ8.61 (d, J = 2.2Hz, 1H), 7.18-7.05 (m, 2H), 7.02-6.97 (m, 2H), 5. 25(dd,J=11.5,9.9Hz,1H),4.46(ddd,J=10.5,8.6,3.1Hz,1H),4.20(dd,J=10.4,8.3Hz, 1H),4.10-4.01(m,1H),3.84-3.59(m,7H),3.59-3.49(m,2H),3.36(ddd,J=18.3,11.6,1 .8Hz, 1H), 3.01-2.96 (m, 1H), 2.89 (d, J = 6.4Hz, 2H), 2.64 (ddd, J = 18.4, 9.9, 1.6Hz, 1H).
[0496] Compound 59: (S)-3-(1-(4-(4-(3-(cyclopropylmethoxy)azetidine-1-carbonyl)-5-fluoropyrimidin-2-yl)piperazine-1-carbonyl)-4,5-dihydro-1H-pyrazol-5-yl)-5-fluorobenzonitrile
[0497]
[0498] Step 1: To a solution of tert-butyl 3-hydroxyazetidine-1-carboxylate (3 g, 17.32 mmol) / DMF (10 ml) was added NaH (60% in oil, 900 mg, 22.5 mmol) at 0°C. The mixture was stirred at room temperature for 1.5 hours, then bromoethylcyclopropane (2.80 g, 20.7 mmol) was slowly added and stirred for 12 hours. The mixture was diluted with EtOAc, washed twice with H2O, once with saturated aqueous NaCl, separated, the organic extracts were dried over Na2SO4, filtered, and the filtrate was concentrated in vacuo, and the resulting residue was subjected to chromatography on silica, eluting with a gradient of 0-20% EtOAc / hexanes to give the title compound (1.7 g) as a colorless oil after solvent evaporation, yield: 43.2%.
[0499] LC-MS (m / z) 228.1 (M+H + ).
[0500] Step 2: To a solution of tert-butyl 3-(cyclopropylmethoxy)azetidine-1-carboxylate (300 mg, 1.32 mmol) in DCM (5 mL) was added TFA (5 mL). The reaction mixture was stirred at 25° C. for 1 hour. The crude product was concentrated under vacuum and used directly in the next step.
[0501] LC-MS (m / z) 128.1 (M+H + ).
[0502] Step 3: The title compound 59, (S)-3-(1-(4-(4-(3-(cyclopropylmethoxy)azetidine-1-carbonyl)-5-fluoropyrimidin-2-yl)piperazine-1-carbonyl)-4,5-dihydro-1H-pyrazol-5-yl)-5-fluorobenzonitrile, was prepared from 3-(cyclopropylmethoxy)azetidine according to the procedure outlined for compound 2 in 36.2% yield.
[0503] LC-MS (m / z) 551.1 (M+H + ).
[0504] 1H NMR(400MHz,DMSO-d6)δ8.61(d,J=2.2Hz,1H),7.78-7.68(m,1H),7.64(s,1H),7.56-7 .44(m,1H),7.11(s,1H),5.29(t,J=10.9Hz,1H),4.51-4.42(m,1H),4.39-4.34(m,1H), 4.30-4.21(m,1H),4.14-4.07(m,1H),3.86(ddd,J=11.0,3.9,1.4Hz,1H),3.79-3.48( m,9H),3.22(d,J=6.9Hz,2H),1.21-1.13(m,1H),0.51-0.43(m,2H),0.20-0.13(m,2H).
[0505] Compound 60: (S)-(5-(3,5-difluorophenyl)-4,5-dihydro-1H-pyrazol-1-yl)(4-(5-fluoro-4-(3-(trifluoromethoxy)azetidine-1-carbonyl)pyrimidin-2-yl)piperazin-1-yl)methanone
[0506]
[0507] Step 1: tert-butyl 3-hydroxyazetidine-1-carboxylate (2.189 g, 12.653 mmol) and Zn(NTf)2 (537.1 mg, 0.837 mmol) and 1-(trifluoromethyl)-1λ 3 -Benzo[d][1,2]iodooxol-3(1H)-one (800 mg, 2.532 mmol) was dissolved in 16.9 ml CHCl3. It was allowed to stir at room temperature for 48 hours. The solvent was evaporated to dryness and purified by column chromatography (PE / EA=10 / 1) to give 45 mg of tert-butyl 3-(trifluoromethoxy)azetidine-1-carboxylate as a yellow oil. LC-MS (m / z): 242.1 [M+H] + .
[0508] Step 2 and Step 3: tert-Butyl 3-(trifluoromethoxy)azetidine-1-carboxylate (45 mg, 0.186 mmol) was dissolved in 1 ml of DCM. To the solution was added 0.2 ml of TFA / DCM (1 / 1) at 0°C. It was allowed to stir at room temperature for 1 hour. The solvent was evaporated to dryness and used in the next step without further purification.
[0509] LC-MS (m / z): 142.2 [M+H] + .
[0510] The above residue and (S)-2-(4-(5-(3,5-difluorophenyl)-4,5-dihydro-1H-pyrazole-1-carbonyl)piperazine-1-yl)-5-fluoropyrimidine-4-carboxylic acid (10 mg, 0.02 mmol) and HATU (11.6 mg, 0.03 mmol) and 0.1 ml of TEA were dissolved in 2 ml of DMF. It was allowed to stir at room temperature for 16 hours. 1 ml of water was added to the solution and extracted with EtOAc (5 ml x 3). The organic layers were combined and evaporated to dryness and purified by preparative HPLC to give 3 mg of (S)-(5-(3,5-difluorophenyl)-4,5-dihydro-1H-pyrazole-1-yl)(4-(5-fluoro-4-(3-(trifluoromethoxy)azetidine-1-carbonyl)pyrimidin-2-yl)piperazine-1-yl)methanone as a white solid. Total yield of two stages: 27%.
[0511] 1 H NMR (400MHz, CDCl3) δ (ppm): 8.35 (d, J = 2.4Hz, 1H), 6.86 (t, J = 1.6Hz, 1H), 6.83-6 .81(m,1H),6.70(tt,J=8.8,2.0Hz,1H),5.33(dd,J=11.2,10.0Hz,1H),5.06-5.00 (m,1H),3.89-3.82(m,3H),3.81-3.70(m,6H),3.68-3.57(m,3H),3.33(ddd,J=18. 4,12.0,1.6Hz,1H),2.69(ddd,J=18.4,10.0,1.6Hz,1H).LC-MS(m / z):558.2[M+H] + .
[0512] Compound 61: (S)-(5-(3,5-difluorophenyl)-4,5-dihydro-1H-pyrazol-1-yl)(4-(4-(2,5-dihydro-1H-pyrrole-1-carbonyl)-5-fluoropyrimidin-2-yl)piperazin-1-yl)methanone
[0513]
[0514] The title compound 61 was prepared in 55.7% yield from (S)-2-(4-(5-(3,5-difluorophenyl)-4,5-dihydro-1H-pyrazole-1-carbonyl)piperazin-1-yl)-5-fluoropyrimidine-4-carbonyl chloride according to the procedure outlined for compound 2.
[0515] LC-MS (m / z) 486.1 (M+H + ).
[0516] 1H NMR (400MHz, DMSO-d6) δ8.62 (d, J = 1.5Hz, 1H), 7.15-7.05 (m, 2H), 7.02-6.97 (m, 2H), 5.97-5.94 (m, 1H), 5.88-5.85 (m, 1H), 5.25 (dd, J=11.5,10.0Hz,1H),4.29-4.21(m,4H),3.80-3.48(m,8H),3.36(ddd,J=18.3,11.6,1.9Hz,1H),2.64(ddd,J=18.3,10.0,1.6Hz,1H).
[0517] Compound 62: (S)-2-(4-(5-(3,5-difluorophenyl)-4,5-dihydro-1H-pyrazole-1-carbonyl)piperazin-1-yl)-5-methoxypyrimidine-4-carboxamide
[0518]
[0519] According to the procedure outlined for compound 67, the title compound 62 was prepared.
[0520] 1 H NMR (400MHz, CDCl3) δ8.35(s,1H),7.39(brs,1H),6.94-6.77(m,3H),6.79-6.57(m,1H),5.74(brs,1H),5.33(dd,J=11. 7,9.9Hz,1H),3.94(s,3H),3.92-3.52(m,8H),3.32(ddd,J=18.3,11.7,1.8Hz,1H),2.69(ddd,J=18.3,9.9,1.6Hz,1H).
[0521] Compound 63: (S)-3-(1-(4-(5-chloro-4-(3-methoxyazetidine-1-carbonyl)pyrimidin-2-yl)piperazine-1-carbonyl)-4,5-dihydro-1H-pyrazol-5-yl)-5-fluorobenzonitrile
[0522]
[0523] Step 1: To a solution of tert-butyl piperazine-1-carboxylate (303 mg, 1.63 mmol) / DMF (10 ml) was added ethyl 2,5-dichloropyrimidine-4-carboxylate (360 mg, 1.63 mmol) and DIPEA (315 mg, 2.44 mmol). The reaction mixture was stirred at 50 ° C for 12 hours. The crude product was purified by silica gel column chromatography. Ethyl 2-(4-(tert-butoxycarbonyl)piperazine-1-yl)-5-chloropyrimidine-4-carboxylate (230 mg, 38%) was obtained as a light yellow solid.
[0524] MS (m / z): 371.1 [M+H] + .
[0525] Step 2: To a solution of ethyl 2-(4-(tert-butoxycarbonyl)piperazine-1-yl)-5-chloropyrimidine-4-carboxylate (150 mg, 404.5 μmol) / THF (6 mL) was added 1N NaOH (6 mL). The reaction mixture was stirred at 45°C for 1 hour. The reaction mixture was acidified by adding 1N HCl. The aqueous layer was extracted twice with EtOAc (100 mL). The combined organic layers were washed with brine (50 mL) and dried over Na2SO4. The solvent was concentrated under vacuum. The crude product was used directly in the next step.
[0526] MS (m / z): 343.1 [M+H] + .
[0527] Step 3: To a solution of 2-(4-(tert-butoxycarbonyl)piperazine-1-yl)-5-chloropyrimidine-4-carboxylic acid (100 mg, 291.7 μmol) / DCM (5 mL) was added 3-methoxyazetidine (31 mg, 350.1 μmol), HATU (333 mg, 875.2 μmol) and DIPEA (0.5 mL). The reaction mixture was stirred at room temperature for 12 hours. The crude product was purified by silica gel column chromatography. tert-Butyl 4-(5-chloro-4-(3-methoxyazetidine-1-carbonyl)pyrimidin-2-yl)piperazine-1-carboxylate (100 mg, 83%) was obtained as a light yellow solid.
[0528] MS (m / z): 412.1 [M+H] + .
[0529] Step 4: To a solution of tert-butyl 4-(5-chloro-4-(3-methoxyazetidine-1-carbonyl)pyrimidin-2-yl)piperazine-1-carboxylate (100 mg, 242.8 μmol) in DCM (5 mL) was added TFA (5 mL). The reaction mixture was stirred at room temperature for 1 hour. The solvent was concentrated under vacuum. The crude product was used directly in the next step.
[0530] MS (m / z): 312.1 [M+H] + .
[0531] Step 5: To a solution of (S)-3-(1-(1H-imidazole-1-carbonyl)-4,5-dihydro-1H-pyrazol-5-yl)-5-fluorobenzonitrile (60 mg, 211.8 μmol) / THF (3 mL) was added (5-chloro-2-(piperazin-1-yl)pyrimidin-4-yl)(3-methoxyazetidin-1-yl)methanone (66 mg, 211.8 μmol) and DIPEA (137 mg, 1.06 mmol). The reaction mixture was stirred at 70° C. for 12 hours. The crude product was purified by Pre-HPLC. (S)-3-(1-(4-(5-chloro-4-(3-methoxyazetidine-1-carbonyl)pyrimidin-2-yl)piperazine-1-carbonyl)-4,5-dihydro-1H-pyrazol-5-yl)-5-fluorobenzonitrile (15 mg, 13%) was obtained as a light yellow solid.
[0532] MS (m / z): 527.1 [M+H] + .
[0533] 1 H NMR(400MHz,DMSO)δ8.55(s,1H),7.75(d,J=9.0Hz,1H),7.21(s,1H),7.12(s,1H),6.66(s,1H), 5.34-5.22(m,1H),4.35-4.15(m,2H),3.95-3.35(m,11H),3.36-3.28(m,1H),2.90-2.84(m,1H).
[0534] Compound 64: (S)-(5-chloro-2-(4-(5-(5-fluoropyridin-3-yl)-4,5-dihydro-1H-pyrazole-1-carbonyl)piperazin-1-yl)pyrimidin-4-yl)(3-methoxyazetidin-1-yl)methanone
[0535]
[0536] The title compound 64 (S)-(5-chloro-2-(4-(5-(5-fluoropyridin-3-yl)-4,5-dihydro-1H-pyrazol-1-yl)(1H-imidazol-1-yl)methanone was prepared according to the procedure outlined for compound 63 in 31% yield from (S)-(5-(5-fluoropyridin-3-yl)-4,5-dihydro-1H-pyrazol-1-yl)(1H-imidazol-1-yl)methanone.
[0537] LC-MS (m / z) 503.1 (M+H + ).
[0538] 1 H NMR (400MHz, DMSO) δ8.59-8.36(m,3H),7.65(d,J=9.9Hz,1H),7.14(s,1H),5.31(t,J=10.9Hz,1H),4. 26(d,J=9.0Hz,5H),3.95-3.48(m,8H),3.39(dd,J=18.3,11.8Hz,1H),3.21(s,3H),2.82-2.65(m,1H).
[0539] Compound 65: (5-chloro-2-(4-(5-(5-chloropyridin-3-yl)-4,5-dihydro-1H-pyrazole-carbonyl)piperazin-1-yl)pyrimidin-4-yl)(3-methoxyazetidin-1-yl)methanone
[0540]
[0541] The title compound 65 (5-chloro-2-(4-(5-(5-chloropyridin-3-yl)-4,5-dihydro-1H-pyrazole-1-carbonyl)piperazin-1-yl)pyrimidin-4-yl)(3-methoxyazetidin-1-yl)methanone was prepared from (5-(5-chloropyridin-3-yl)-4,5-dihydro-1H-pyrazol-1-yl)(1H-imidazol-1-yl)methanone in 33% yield according to the procedure outlined for compound 63.
[0542] LC-MS (m / z) 519.1 (M+H + ).
[0543] 1 H NMR (300MHz, DMSO-d6) δ8.59-8.41(m,2H),8.35-8.23(m,1H),7.82(t,J=2.0Hz,1H),7.13-7.11(m,1H),5.25(t,J=10. 8Hz,1H),4.26-4.19(m,3H),3.91-3.81(m,1H),3.77-3.28(m,8H),3.18(s,3H),3.16-3.07(m,2H),2.78-2.71(m,1H).
[0544] Compound 66: (5-(5-chloropyridin-3-yl)-4,5-dihydro-1H-pyrazol-1-yl)(4-(5-fluoro-4-(3-methoxyazetidine-1-carbonyl)pyrimidin-2-yl)piperazin-1-yl)methanone
[0545] The title compound 66 (5-(5-chloropyridin-3-yl)-4,5-dihydro-1H-pyrazol-1-yl)(4-(5-fluoro-4-(3-methoxyazetidine-1-carbonyl)pyrimidin-2-yl)piperazin-1-yl)methanone was prepared from (5-(5-chloropyridin-3-yl)-4,5-dihydro-1H-pyrazol-1-yl)(1H-imidazol-1-yl)methanone in 35% yield according to the procedure outlined for compound 63.
[0546] LC-MS (m / z) 503.1 (M+H + ).
[0547] 1 H NMR (300MHz, DMSO-d6) δ8.60-8.46(m,3H),7.83(t,J=2.1Hz,1H),7.13(d,J=1.6Hz,1H),5.27(t,J=10.8Hz,1H),4.47-4.40(m,1H ),4.28-4.20(m,3H),4.10-4.03(m,1H),3.88-3.82(m,1H),3.78-3.48(m,8H),3.42-3.31(m,1H),3.21(s,3H),2.78-2.71(m,1H).
[0548] Compound 67: (S)-4-(4-(5-(3,5-difluorophenyl)-4,5-dihydro-1H-pyrazole-1-carbonyl)piperazin-1-yl)-5-fluoro-2-pyridineamide
[0549]
[0550] Step 1: Mix 2-chloro-5-fluoro-4-iodopyridine (1.84 g, 7.16 mmol) and tert-butyl piperazine-1-carboxylate (2.0 g, 10.7 mmol), Pd2(dba)3 (655 mg), Xphos (341 mg) and Cs2CO3 (3.49 g, 10.74 mmol) in 30 ml of toluene. Let it stir at 110°C for 16 hours. Evaporate the solvent and purify by chromatography (PE / EA=4 / 1) to give 1.5 g of brown oil.
[0551] Yield: 66.4%.
[0552] LC-MS (m / z): 316.4 [M+H] + .
[0553] Step 2: To a stirred solution of tert-butyl 4-(2-chloro-5-fluoropyridin-4-yl)piperazine-1-carboxylate (640 mg, 2 mmol) and Zn(CN)2 (240 mg, 2 mmol) / DMF (10 ml) at room temperature under N2 atmosphere were added Zn powder (30 mg, 0.5 mmol), Pd2(dba)3 (180 mg, 0.2 mmol) and DPPF (110 mg, 0.2 mmol). The resulting mixture was stirred at 100°C for another 2 hours. The mixture was cooled to room temperature. The resulting mixture was filtered and the filter cake was washed with EA (3×50 ml). The filtrate was concentrated under reduced pressure. The residue was purified by column chromatography (PE / EA=82 / 18) to give 400 mg of tert-butyl 4-(2-cyano-5-fluoropyridin-4-yl)piperazine-1-carboxylate as a yellow solid (yield: 35.3%).
[0554] LC-MS (m / z): 307.4 [M+H] + .
[0555] Step 3 and Step 4: (S)-4-(4-(5-(3,5-difluorophenyl)-4,5-dihydro-1H-pyrazole-1-carbonyl)piperazin-1-yl)-5-fluoro-2-cyanopyridine was synthesized as an off-white solid according to the procedure for compound 63. Yield: 21.7%.
[0556] 1 H NMR (400 MHz, chloroform-d) δ 8.27 (d, J = 5.4 Hz, 1H), 7.12 (d, J = 7.1 Hz, 1H), 6.87 (t, J = 1.7 Hz, 1H), 6.84-6.76 (m, 2H), 6.71 (tt, J = 8.8, 2.3 Hz, 1H), 5.32 (dd, J = 11.7, 9.6 Hz, 1H ),3.87(ddd,J=13.4,7.3,3.3Hz,2H),3.72(ddd,J=13.4,6.7,3.3Hz,2H),3.45(dd d,J=12.4,6.7,3.3Hz,2H),3.40-3.26(m,3H),2.71(ddd,J=18.4,9.7,1.6Hz,1H).
[0557] Mass spectrum (m / z): 415.2 [M+H] + .
[0558] Step 5: (S)-4-(4-(5-(3,5-difluorophenyl)-4,5-dihydro-1H-pyrazole-1-carbonyl)piperazin-1-yl)-5-fluoro-2-cyanopyridine (61 mg, 0.147 mmol) was dissolved in 2 ml MeOH. 0.3 ml 30% H2O2 and 0.15 ml 2N NaOH were added. It was stirred at room temperature for 30 minutes. The solvent was evaporated to dryness and purified by preparative TLC (DCM / MeOH=25 / 1) to give 35 mg of compound 67 as a white solid. Yield: 54.9%.
[0559] 1 H NMR (400 MHz, CHLOROFORM-d) δ 8.15 (d, J = 5.2 Hz, 1H), 7.71 (d, J = 7.7 Hz, 2H), 6.89-6.78 (m, 3H), 6.70 (tt, J = 8.9, 2.3 Hz, 1H), 5.68 (s, 1H), 5.32 (dd, J = 11.7, 9.8 Hz, 1H), 3.85 (ddd, J = 13.3, 7.2, 3.2 Hz, 2H), 3.70 (ddd, J = 13.3, 6.7, 3.2 Hz, 2H), 3.45 (ddd, J = 12.4, 6.8, 3.3 Hz, 2H), 3.41-3.23 (m, 3H), 2.69 (ddd, J = 18.3, 9.8, 1.7 Hz, 1H).
[0560] Mass spectrum (m / z): 433.2 [M+H] + .
[0561] Example 2
[0562] Biological analysis
[0563] Compounds 1-67 of the present disclosure (indicated as Compounds 1-67 in Table 1) were tested for binding and cellular RIP1 inhibitory activity according to the following experimental procedures.
[0564] Material
[0565] Cell line: HT-29 ( HTB-38 TM )
[0566] Culture medium: McCoy's 5A, Gibco, Cat No. 16600-082
[0567] FBS,Gibco,Cat No.10099-141C
[0568] Trypsin: Gibco, Cat No. 25200-056
[0569] DMSO:Sigma,Cat No.67-68-5,1L
[0570] Assay plate: Corning #3903
[0571] Compound dilution plate: Corning #3357
[0572] Inducer: TNFα, GenScript, Cat No. Z01001-50,
[0573] SmacM,Cat.No.,HY-15989,MedChemExpress(MCE)
[0574] Z VAD FMK,TargetMol,T6013
[0575] Cell Titer- Luminescent Cell Viability Assay Kit: Promega, Cat No. G7573
[0576] EnVision:PerkinElmer,2105-0010
[0577] method
[0578] Cell seeding
[0579] 1. Check HT-29 cells daily to ensure they are healthy and growing as expected. When they are approximately 80% confluent, sub-culturing them.
[0580] 2. Pre-warm the culture medium, McCoy's 5A medium (Gibco, Cat No. 16600-082) with 10% fetal bovine serum or FBS (Gibco, Cat No. 10099-141C) in a 37°C water bath for at least 30 minutes.
[0581] 3. When cells reach 80% of desired confluency in T75 flasks, aspirate media and wash cells twice with warm phosphate-buffered saline or PBS.
[0582] 4. Add 2-3 ml of fresh warm trypsin (Gibco, Cat No. 25200-056) solution to the washed cells. Transfer the flask containing cells to a 37°C incubator.
[0583] 5. After 5 minutes, tap the side of the flask and examine the flask under a microscope to see if the cells have detached from the flask. If necessary, keep the cells in the incubator for an additional 5-10 minutes with occasional tapping until climbing is complete.
[0584] 6. Neutralize the trypsin reaction by transferring 6-9 ml of cell culture media to a sterile 15 ml conical tube and pellet the cells by centrifuging the cell culture at 300 x g for 7 minutes (decant the supernatant).
[0585] 7. Resuspend the cells in fresh cell culture medium and count the cells using a hemacytometer.
[0586] 8. Transfer 100 μl of the resuspended cell culture medium containing approximately 5000 cells to each well of a sterile 96-well cell culture plate (Corning 3903) and incubate overnight at 37°C with 5% CO2.
[0587] Compound titration and handling
[0588] 1. All test compounds were dissolved in DMSO (dimethyl sulfoxide) to make 20 mM stock solutions.
[0589] 2. 3 μl of 20 mM stock solution of each compound was mixed with 27 μl DMSO, and the compound solution was further diluted at a titration ratio of 1:3 (20 μl compound solution + 40 μl DMSO) until the 10-point stop.
[0590] 3. Remove all the culture medium from the assay plate filled with HT-29 cell culture. Then wash the cells with 1 PBS and resuspend them in fresh McCoy's 5A medium without FBS (the medium contains a cocktail of TNF-α (10 ng / ml), SMAC mimetic compound (6 μM) and Z-VAD-fluoromethylketone or zVAD-FMK (10 μM)) to stimulate HT-29 cells to increase RIP1 kinase level and cell necroptosis.
[0591] 4. Add 0.5 μl of the diluted compound solution into the corresponding 96-well assay plate.
[0592] 5. Incubate the assay plate at 37°C with 5% CO2 for 20 hours.
[0593] Cell viability assay
[0594] 1. Use CellTiter- Luminescent Cell Viability Assay was used to detect the ATP level of viable HT-29 cells.
[0595] 2. Before use, add CellTiter- Buffer and lyophilized substrate were equilibrated to room temperature.
[0596] 3. CellTiter- Substrate CellTiter- The buffer was resuspended and then mixed by gently vortexing to obtain a homogenous solution.
[0597] 4. Transfer 20 μl of the enzyme / substrate mixture to a 96-well assay plate using a multichannel pipette.
[0598] 5. Place the assay plate on an orbital shaker and shake the contents for 3 minutes to induce cell lysis.
[0599] 6. Incubate the assay plate at room temperature for 10 minutes to stabilize the luminescent signal.
[0600] 7. Read and record the luminescence signal using EnVision.
[0601] 8. Geometric mean EC50 values were calculated from 10-point response doses in duplicate. The range of EC50 values for compounds 1-67 is included in Table 2.
Claims
1. A compound, a salt thereof, or a stereoisomer thereof, wherein the compound is selected from the group consisting of:
2. A pharmaceutical composition in a predetermined unit dosage form, comprising a therapeutically effective amount of a compound of claim 1, a salt thereof, or a stereoisomer thereof, and one or more pharmaceutically acceptable excipients.
3. Use of the compound of claim 1, its salt, or its stereoisomer or the composition of claim 2 in the manufacture of a medicament for inhibiting necrosis, ferroptosis, human RIP1, or related indications in a human in need thereof.
4. Use of the compound of claim 1, its salt, or its stereoisomer or the composition of claim 2 in the manufacture of a medicament for inhibiting necroptosis, ferroptosis, human RIP1, or related indications in a human in need thereof.
